{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:52:23Z","timestamp":1784872343745,"version":"3.55.0"},"reference-count":288,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04686-5","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:03:28Z","timestamp":1782929008000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6895-3721","authenticated-orcid":false,"given":"Irshad","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4467-6646","authenticated-orcid":false,"given":"Sarasa","family":"Meenakshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-0498","authenticated-orcid":false,"given":"Md.","family":"Abubakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4929-3954","authenticated-orcid":false,"given":"Nitesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3368-4467","authenticated-orcid":false,"given":"Vinod L","family":"Gaikwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1318-2259","authenticated-orcid":false,"given":"Amita","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9865-7454","authenticated-orcid":false,"given":"Krishna","family":"Murti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"4686_CR1","doi-asserted-by":"crossref","unstructured":"F. Zakir, S. Mohapatra, U. Farooq, M.A. Mirza, Z. Iqbal, Chapter 1 - Introduction to metabolic disorders, in Drug Delivery Systems for Metabolic Disorders, ed. by H. Dureja, S.N. Murthy, P.R. Wich, K. Dua (Academic, 2022), pp. 1\u201320","DOI":"10.1016\/B978-0-323-99616-7.00001-3"},{"issue":"10","key":"4686_CR2","doi-asserted-by":"publisher","first-page":"e0240971","DOI":"10.1371\/journal.pone.0240971","volume":"15","author":"Y Krishnamoorthy","year":"2020","unstructured":"Y. Krishnamoorthy, S. Rajaa, S. Murali, T. Rehman, J. Sahoo, S.S. Kar, Prevalence of metabolic syndrome among adult population in India: A systematic review and meta-analysis. PLoS One. 15(10), e0240971 (2020)","journal-title":"PLoS One"},{"issue":"11 Suppl 1","key":"4686_CR3","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1210\/jc.2008-1595","volume":"93","author":"A Misra","year":"2008","unstructured":"A. Misra, L. Khurana, Obesity and the metabolic syndrome in developing countries. J. Clin. Endocrinol. Metab. 93(11 Suppl 1), S9\u201330 (2008)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4686_CR4","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"P. Saeedi, I. Petersohn, P. Salpea, B. Malanda, S. Karuranga, N. Unwin et al., Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res. Clin. Pract. 157, 107843 (2019)","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"11","key":"4686_CR5","doi-asserted-by":"publisher","first-page":"2400314","DOI":"10.1002\/smsc.202400314","volume":"4","author":"JJ Kim","year":"2024","unstructured":"J.J. Kim, M. Bae, D.W. Cho, Multi-Organ Microphysiological Systems Targeting Specific Organs for Recapitulating Disease Phenotypes via Organ Crosstalk. Small Sci. 4(11), 2400314 (2024)","journal-title":"Small Sci."},{"issue":"4","key":"4686_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41574-021-00626-7","volume":"18","author":"JA Amorim","year":"2022","unstructured":"J.A. Amorim, G. Coppotelli, A.P. Rolo, C.M. Palmeira, J.M. Ross, D.A. Sinclair, Mitochondrial and metabolic dysfunction in ageing and age-related diseases. Nat. reviews Endocrinol. 18(4), 243\u2013258 (2022)","journal-title":"Nat. reviews Endocrinol."},{"issue":"1","key":"4686_CR7","first-page":"9828672","volume":"2016","author":"S Chaturvedi","year":"2016","unstructured":"S. Chaturvedi, A.K. Singh, A.K. Keshari, S. Maity, S. Sarkar, S. Saha, Human Metabolic Enzymes Deficiency: A Genetic Mutation Based Approach. Scientifica (Cairo). 2016(1), 9828672 (2016)","journal-title":"Scientifica (Cairo)"},{"issue":"1","key":"4686_CR8","first-page":"72","volume":"14","author":"A Caturano","year":"2025","unstructured":"A. Caturano, M. Rocco, G. Tagliaferri, A. Piacevole, D. Nilo, G. Di, Lorenzo et al., Oxidative Stress and Cardiovascular Complications in Type 2 Diabetes: From Pathophysiology to Lifestyle Modifications. Antioxid. (Basel Switzerland). 14(1), 72 (2025)","journal-title":"Antioxid. (Basel Switzerland)"},{"key":"4686_CR9","doi-asserted-by":"crossref","unstructured":"F. Zakir, S. Mohapatra, U. Farooq, M.A. Mirza, Z. Iqbal, Introduction to metabolic disorders. Drug delivery systems for metabolic disorders (Elsevier, 2022), pp. 1\u201320","DOI":"10.1016\/B978-0-323-99616-7.00001-3"},{"issue":"6","key":"4686_CR10","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.drudis.2015.02.002","volume":"20","author":"MS Kinch","year":"2015","unstructured":"M.S. Kinch, S. Umlauf, M. Plummer, An analysis of FDA-approved drugs for metabolic diseases. Drug Discov Today. 20(6), 648\u2013651 (2015)","journal-title":"Drug Discov Today"},{"issue":"4","key":"4686_CR11","first-page":"884","volume":"19","author":"B Mitrovic","year":"2023","unstructured":"B. Mitrovic, Z.M. Gluvic, M. Obradovic, M. Radunovic, M. Rizzo, M. Banach et al., Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today? Arch. Med. Sci. 19(4), 884\u2013894 (2023)","journal-title":"Arch. Med. Sci."},{"issue":"3","key":"4686_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4103\/2221-1691.338919","volume":"12","author":"RF Abdel-Rahman","year":"2022","unstructured":"R.F. Abdel-Rahman, Non-alcoholic fatty liver disease. Asian Pac. J. Trop. Biomed. 12(3), 99\u2013114 (2022)","journal-title":"Asian Pac. J. Trop. Biomed."},{"issue":"9491","key":"4686_CR13","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","volume":"366","author":"KG Alberti","year":"2005","unstructured":"K.G. Alberti, P. Zimmet, J. Shaw, I.D.F.E.T.F.C. Group, The metabolic syndrome\u2013a new worldwide definition. Lancet. 366(9491), 1059\u20131062 (2005)","journal-title":"Lancet"},{"issue":"10300","key":"4686_CR14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"B. Ludvik, F. Giorgino, E. Jodar, J.P. Frias, L. Fernandez Lando, K. Brown et al., Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 398(10300), 583\u2013598 (2021)","journal-title":"Lancet"},{"key":"4686_CR15","doi-asserted-by":"publisher","first-page":"1149239","DOI":"10.3389\/fendo.2023.1149239","volume":"14","author":"X Zhao","year":"2023","unstructured":"X. Zhao, X. An, C. Yang, W. Sun, H. Ji, F. Lian, The crucial role and mechanism of insulin resistance in metabolic disease. Front. Endocrinol. (Lausanne). 14, 1149239 (2023)","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"4","key":"4686_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1161\/CIRCRESAHA.107.165472","volume":"102","author":"JA Kim","year":"2008","unstructured":"J.A. Kim, Y. Wei, J.R. Sowers, Role of mitochondrial dysfunction in insulin resistance. Circul. Res. 102(4), 401\u2013414 (2008)","journal-title":"Circul. Res."},{"key":"4686_CR17","doi-asserted-by":"publisher","first-page":"508409","DOI":"10.1155\/2015\/508409","volume":"2015","author":"L Chen","year":"2015","unstructured":"L. Chen, R. Chen, H. Wang, F. Liang, Mechanisms Linking Inflammation to Insulin Resistance. Int. J. Endocrinol. 2015, 508409 (2015)","journal-title":"Int. J. Endocrinol."},{"issue":"4","key":"4686_CR18","doi-asserted-by":"publisher","first-page":"e230112","DOI":"10.1530\/JME-23-0112","volume":"72","author":"M Santos-Hern\u00e1ndez","year":"2024","unstructured":"M. Santos-Hern\u00e1ndez, F. Reimann, F.M. Gribble, Cellular mechanisms of incretin hormone secretion. J. Mol. Endocrinol. 72(4), e230112 (2024)","journal-title":"J. Mol. Endocrinol."},{"issue":"1","key":"4686_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4103\/jod.jod_117_23","volume":"15","author":"B Pal","year":"2024","unstructured":"B. Pal, M. Chattopadhyay, Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology. J. Diabetol. 15(1), 24\u201337 (2024)","journal-title":"J. Diabetol."},{"issue":"8","key":"4686_CR20","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1039\/D3MD00107E","volume":"14","author":"B Pati","year":"2023","unstructured":"B. Pati, S. Sendh, B. Sahu, S. Pani, N. Jena, N. C.J.R, Recent advancements in pharmacological strategies to modulate energy balance for combating obesity. RSC Med. Chem. 14(8), 1429\u20131445 (2023)","journal-title":"RSC Med. Chem."},{"key":"4686_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","volume":"18","author":"T Coskun","year":"2018","unstructured":"T. Coskun, K.W. Sloop, C. Loghin, J. Alsina-Fernandez, S. Urva, K.B. Bokvist et al., LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol. Metab. 18, 3\u201314 (2018)","journal-title":"Mol. Metab."},{"issue":"13","key":"4686_CR22","doi-asserted-by":"publisher","first-page":"e2116506119","DOI":"10.1073\/pnas.2116506119","volume":"119","author":"B Sun","year":"2022","unstructured":"B. Sun, F.S. Willard, D. Feng, J. Alsina-Fernandez, Q. Chen, M. Vieth et al., Structural determinants of dual incretin receptor agonism by tirzepatide. Proc. Natl. Acad. Sci. U S A 119(13), e2116506119 (2022)","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"19","key":"4686_CR23","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.2174\/0115680266293416240515075450","volume":"24","author":"M Abubakar","year":"2024","unstructured":"M. Abubakar, L. Nama, M.A. Ansari, M.M. Ansari, S. Bhardwaj, R. Daksh et al., GLP-1\/GIP Agonist as an Intriguing and Ultimate Remedy for Combating Alzheimer\u2019s Disease through its Supporting DPP4 Inhibitors: A Review. Curr. Top. Med. Chem. 24(19), 1635\u20131664 (2024)","journal-title":"Curr. Top. Med. Chem."},{"issue":"6","key":"4686_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","volume":"17","author":"JE Campbell","year":"2013","unstructured":"J.E. Campbell, D.J. Drucker, Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabol. 17(6), 819\u2013837 (2013)","journal-title":"Cell Metabol."},{"issue":"4","key":"4686_CR25","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/dom.13595","volume":"21","author":"Y Xiang","year":"2019","unstructured":"Y. Xiang, G. Huang, Y. Zhu, X. Zuo, X. Liu, Q. Feng et al., Identification of autoimmune type 1 diabetes and multiple organ-specific autoantibodies in adult-onset non-insulin-requiring diabetes in China: A population-based multicentre nationwide survey. Diabetes Obes. Metab. 21(4), 893\u2013902 (2019)","journal-title":"Diabetes Obes. Metab."},{"issue":"17","key":"4686_CR26","doi-asserted-by":"publisher","first-page":"e140532","DOI":"10.1172\/jci.insight.140532","volume":"5","author":"FS Willard","year":"2020","unstructured":"F.S. Willard, J.D. Douros, M.B. Gabe, A.D. Showalter, D.B. Wainscott, T.M. Suter et al., Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 5(17), e140532 (2020)","journal-title":"JCI Insight"},{"issue":"6","key":"4686_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/17446651.2024.2395540","volume":"19","author":"SA Rabbani","year":"2024","unstructured":"S.A. Rabbani, M. El-Tanani, I.I. Matalka, I.R. Rangraze, A.A.A. Aljabali, M.A. Khan et al., Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management. Expert Rev. Endocrinol. Metab. 19(6), 487\u2013505 (2024)","journal-title":"Expert Rev. Endocrinol. Metab."},{"issue":"3","key":"4686_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.pcd.2025.03.008","volume":"19","author":"S Sokary","year":"2025","unstructured":"S. Sokary, H. Bawadi, The promise of tirzepatide: A narrative review of metabolic benefits. Prim. Care Diabetes. 19(3), 229\u2013237 (2025)","journal-title":"Prim. Care Diabetes"},{"key":"4686_CR29","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2147\/DMSO.S443396","volume":"17","author":"X Lv","year":"2024","unstructured":"X. Lv, H. Wang, C. Chen, Y. Zhao, K. Li, Y. Wang et al., The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight\/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes, metabolic syndrome and obesity: targets and therapy. 17, 701\u2009\u2013\u200914 (2024)","journal-title":"Diabetes, metabolic syndrome and obesity: targets and therapy"},{"key":"4686_CR30","doi-asserted-by":"crossref","unstructured":"S. Allocca, A. Monda, A. Messina, M. Casillo, W. Sapuppo, V. Monda et al., Endocrine and Metabolic Mechanisms Linking Obesity to Type 2 Diabetes: Implications for Targeted Therapy. Healthcare (Basel, Switzerland). 13(12) (2025)","DOI":"10.3390\/healthcare13121437"},{"issue":"1","key":"4686_CR31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s41232-023-00306-1","volume":"43","author":"H Katagiri","year":"2023","unstructured":"H. Katagiri, Inter-organ communication involved in metabolic regulation at the whole-body level. Inflamm. regeneration. 43(1), 60 (2023)","journal-title":"Inflamm. regeneration"},{"issue":"1","key":"4686_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1172\/JCI60016","volume":"122","author":"RH Unger","year":"2012","unstructured":"R.H. Unger, A.D. Cherrington, Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J. Clin. Investig. 122(1), 4\u201312 (2012)","journal-title":"J. Clin. Investig."},{"issue":"6","key":"4686_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrn3745","volume":"15","author":"GJ Morton","year":"2014","unstructured":"G.J. Morton, T.H. Meek, M.W. Schwartz, Neurobiology of food intake in health and disease. Nat. Rev. Neurosci. 15(6), 367\u2013378 (2014)","journal-title":"Nat. Rev. Neurosci."},{"issue":"Suppl 2","key":"4686_CR34","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1007\/s12072-024-10660-y","volume":"18","author":"J Zhao","year":"2024","unstructured":"J. Zhao, L. Liu, Y.Y. Cao, X. Gao, G. Targher, C.D. Byrne et al., MAFLD as part of systemic metabolic dysregulation. Hep. Intl. 18(Suppl 2), 834\u2013847 (2024)","journal-title":"Hep. Intl."},{"issue":"1","key":"4686_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000368898","volume":"83","author":"C Posovszky","year":"2014","unstructured":"C. Posovszky, M. Wabitsch, Regulation of Appetite, Satiation, and Body Weight by Enteroendocrine Cells. Part 1: Characteristics of Enteroendocrine Cells and Their Capability of Weight Regulation. Hormone Res. Paediatrics. 83(1), 1\u201310 (2014)","journal-title":"Hormone Res. Paediatrics"},{"issue":"4","key":"4686_CR36","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"D.J. Drucker, Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell. Metab. 27(4), 740\u2013756 (2018)","journal-title":"Cell. Metab."},{"issue":"2","key":"4686_CR37","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1152\/physrev.00025.2016","volume":"97","author":"TD M\u00fcller","year":"2017","unstructured":"T.D. M\u00fcller, B. Finan, C. Clemmensen, R.D. DiMarchi, M.H. Tsch\u00f6p, The New Biology and Pharmacology of Glucagon. Physiol. Rev. 97(2), 721\u2013766 (2017)","journal-title":"Physiol. Rev."},{"issue":"5","key":"4686_CR38","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s10620-016-4054-0","volume":"61","author":"S Softic","year":"2016","unstructured":"S. Softic, D.E. Cohen, C.R. Kahn, Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease. Dig. Dis. Sci. 61(5), 1282\u20131293 (2016)","journal-title":"Dig. Dis. Sci."},{"issue":"5","key":"4686_CR39","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3390\/biomedicines11051290","volume":"11","author":"VJ Clemente-Suarez","year":"2023","unstructured":"V.J. Clemente-Suarez, L. Redondo-Florez, A.I. Beltran-Velasco, A. Martin-Rodriguez, I. Martinez-Guardado, E. Navarro-Jimenez et al., The Role of Adipokines in Health and Disease. Biomedicines. 11(5), 1290 (2023)","journal-title":"Biomedicines"},{"issue":"11","key":"4686_CR40","doi-asserted-by":"publisher","first-page":"9453","DOI":"10.3390\/nu7115475","volume":"7","author":"C Saponaro","year":"2015","unstructured":"C. Saponaro, M. Gaggini, F. Carli, A. Gastaldelli, The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis. Nutrients. 7(11), 9453\u20139474 (2015)","journal-title":"Nutrients"},{"issue":"13","key":"4686_CR41","first-page":"1391","volume":"137","author":"IJ Neeland","year":"2018","unstructured":"I.J. Neeland, P. Poirier, J.-P. Despr\u00e9s, Cardiovasc. Metabolic Heterogeneity Obes. 137(13), 1391\u20131406 (2018)","journal-title":"Cardiovasc. Metabolic Heterogeneity Obes."},{"key":"4686_CR42","doi-asserted-by":"publisher","first-page":"170194","DOI":"10.1016\/j.peptides.2019.170194","volume":"125","author":"AE Adriaenssens","year":"2020","unstructured":"A.E. Adriaenssens, F.M. Gribble, F. Reimann, The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system. Peptides. 125, 170194 (2020)","journal-title":"Peptides"},{"issue":"5","key":"4686_CR43","doi-asserted-by":"publisher","first-page":"E595","DOI":"10.1152\/ajpendo.00236.2023","volume":"325","author":"F Folli","year":"2023","unstructured":"F. Folli, G. Finzi, R. Manfrini, A. Galli, F. Casiraghi, L. Centofanti et al., Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets. Am. J. Physiol. Endocrinol. Metab. 325(5), E595\u2013E609 (2023)","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"4686_CR44","doi-asserted-by":"publisher","first-page":"1431292","DOI":"10.3389\/fendo.2024.1431292","volume":"15","author":"QK Liu","year":"2024","unstructured":"Q.K. Liu, Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front. Endocrinol. (Lausanne). 15, 1431292 (2024)","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"2","key":"4686_CR45","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/30502071251336542","volume":"1","author":"KG Seshadri","year":"2025","unstructured":"K.G. Seshadri, Biased Agonism in Incretin-based Therapies. Int. J. Clin. Metabolism Diabetes. 1(2), 96\u2013101 (2025)","journal-title":"Int. J. Clin. Metabolism Diabetes"},{"issue":"2","key":"4686_CR46","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/j.2040-4603.2020.tb00126.x","volume":"10","author":"A Kowluru","year":"2020","unstructured":"A. Kowluru, G. GPCRs, Proteins, and Their Impact on beta-cell Function. Compr. Physiol. 10(2), 453\u2013490 (2020)","journal-title":"Compr. Physiol."},{"issue":"3","key":"4686_CR47","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1038\/emm.2016.6","volume":"48","author":"PV Roder","year":"2016","unstructured":"P.V. Roder, B. Wu, Y. Liu, W. Han, Pancreatic regulation of glucose homeostasis. Exp. Mol. Med. 48(3), e219 (2016)","journal-title":"Exp. Mol. Med."},{"issue":"7","key":"4686_CR48","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.3390\/cells10071658","volume":"10","author":"A Stozer","year":"2021","unstructured":"A. Stozer, E. Paradiz Leitgeb, V. Pohorec, J. Dolensek, L. Krizancic Bombek, M. Gosak et al., The Role of cAMP in Beta Cell Stimulus-Secretion and Intercellular Coupling. Cells. 10(7), 1658 (2021)","journal-title":"Cells"},{"issue":"15","key":"4686_CR49","doi-asserted-by":"publisher","first-page":"8202","DOI":"10.3390\/ijms25158202","volume":"25","author":"M Nicze","year":"2024","unstructured":"M. Nicze, A. Dec, M. Bor\u00f3wka, D. Krzy\u017cak, A. Bo\u0142dys, \u0141. Bu\u0142dak et al., Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy. Int. J. Mol. Sci. 25(15), 8202 (2024)","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"4686_CR50","first-page":"7","volume":"8","author":"S Acreman","year":"2022","unstructured":"S. Acreman, Q. Zhang, Regulation of alpha-cell glucagon secretion: The role of second messengers. Chronic Dis. Transl Med. 8(1), 7\u201318 (2022)","journal-title":"Chronic Dis. Transl Med."},{"issue":"4","key":"4686_CR51","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/bph.15603","volume":"179","author":"DI Brierley","year":"2022","unstructured":"D.I. Brierley, de G. Lartigue, Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating. Br. J. Pharmacol. 179(4), 584\u2013599 (2022)","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"4686_CR52","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13578-022-00914-3","volume":"12","author":"I Singh","year":"2022","unstructured":"I. Singh, L. Wang, B. Xia, J. Liu, A. Tahiri, El A. Ouaamari et al., Activation of arcuate nucleus glucagon-like peptide-1 receptor-expressing neurons suppresses food intake. Cell. Biosci. 12(1), 178 (2022)","journal-title":"Cell. Biosci."},{"issue":"9","key":"4686_CR53","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.cmet.2023.07.010","volume":"35","author":"JE Campbell","year":"2023","unstructured":"J.E. Campbell, T.D. Muller, B. Finan, R.D. DiMarchi, M.H. Tschop, D.A. D\u2019Alessio, GIPR\/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications. Cell. Metab. 35(9), 1519\u20131529 (2023)","journal-title":"Cell. Metab."},{"issue":"5","key":"4686_CR54","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/ckj\/sfac274","volume":"16","author":"C Bosch","year":"2023","unstructured":"C. Bosch, S. Carriazo, M.J. Soler, A. Ortiz, B. Fernandez-Fernandez, Tirzepatide and prevention of chronic kidney disease. Clin. kidney J. 16(5), 797\u2013808 (2023)","journal-title":"Clin. kidney J."},{"key":"4686_CR55","doi-asserted-by":"crossref","unstructured":"A. Regmi, E. Aihara, M.E. Christe, G. Varga, T.P. Beyer, X. Ruan et al., Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell metabolism. 36(7), 1534-49.e7 (2024)","DOI":"10.1016\/j.cmet.2024.05.010"},{"issue":"5","key":"4686_CR56","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/db21-1166","volume":"71","author":"JE Campbell","year":"2022","unstructured":"J.E. Campbell, J.L. Beaudry, B. Svendsen, L.L. Baggio, A.N. Gordon, J.R. Ussher et al., GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue. Diabetes. 71(5), 1115\u20131127 (2022)","journal-title":"Diabetes"},{"issue":"19","key":"4686_CR57","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.3390\/nu16193245","volume":"16","author":"M Radziszewska","year":"2024","unstructured":"M. Radziszewska, L. Ostrowska, J. Smarkusz-Zarzecka, The Impact of Gastrointestinal Hormones on Human Adipose Tissue Function. Nutrients. 16(19), 3245 (2024)","journal-title":"Nutrients"},{"issue":"11","key":"4686_CR58","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s40618-023-02125-0","volume":"46","author":"VA Genchi","year":"2023","unstructured":"V.A. Genchi, G. Palma, G.P. Sorice, R. D\u2019Oria, C. Caccioppoli, N. Marrano et al., Pharmacological modulation of adaptive thermogenesis: new clues for obesity management? J. Endocrinol. Invest. 46(11), 2213\u20132236 (2023)","journal-title":"J. Endocrinol. Invest."},{"key":"4686_CR59","doi-asserted-by":"publisher","first-page":"106411","DOI":"10.1016\/j.phrs.2022.106411","volume":"184","author":"L El Eid","year":"2022","unstructured":"El L. Eid, C.A. Reynolds, A. Tomas, J. Ben, Biased agonism and polymorphic variation at the GLP-1 receptor: Implications for the development of personalised therapeutics. Pharmacol. Res. 184, 106411 (2022)","journal-title":"Pharmacol. Res."},{"issue":"9","key":"4686_CR60","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.2337\/dbi21-0004","volume":"70","author":"MR Hayes","year":"2021","unstructured":"M.R. Hayes, T. Borner, De B.C. Jonghe, The Role of GIP in the Regulation of GLP-1 Satiety and Nausea. Diabetes. 70(9), 1956\u20131961 (2021)","journal-title":"Diabetes"},{"issue":"7","key":"4686_CR61","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2174\/0115665240298668240528110159","volume":"25","author":"JA Nogueira-Machado","year":"2025","unstructured":"J.A. Nogueira-Machado, N.A. Gomes, F. Rocha-Silva, The AMPK\/cAMP Metabolic Signaling Axis as a Possible Therapeutic Target for Diabetes. Curr. Mol. Med. 25(7), 785\u2013791 (2025)","journal-title":"Curr. Mol. Med."},{"issue":"1","key":"4686_CR62","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1097\/MJT.0000000000001588","volume":"30","author":"E Wong","year":"2023","unstructured":"E. Wong, R. Cope, L. Dima, T. Nguyen, Tirzepatide, A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus. Am. J. Ther. 30(1), e26\u2013e35 (2023)","journal-title":"Am. J. Ther."},{"issue":"1","key":"4686_CR63","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41467-022-28683-0","volume":"13","author":"F Zhao","year":"2022","unstructured":"F. Zhao, Q. Zhou, Z. Cong, K. Hang, X. Zou, C. Zhang et al., Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nat. Commun. 13(1), 1057 (2022)","journal-title":"Nat. Commun."},{"issue":"3","key":"4686_CR64","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/psp4.13099","volume":"13","author":"K Schneck","year":"2024","unstructured":"K. Schneck, S. Urva, Population pharmacokinetics of the GIP\/GLP receptor agonist tirzepatide. CPT Pharmacometrics Syst. Pharmacol. 13(3), 494\u2013503 (2024)","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"02","key":"4686_CR65","doi-asserted-by":"publisher","first-page":"404","DOI":"10.25258\/ijpqa.14.2.27","volume":"14","author":"BD Prasad","year":"2023","unstructured":"B.D. Prasad, R. Godela, N.R.K. Sirisha, P. Goud, QbD Approach for Analysis of Tirzepatide in its Bulk and Marketed Formulation by Stability Indicating RP-HPLC. Int. J. Pharm. Qual. Assur. 14(02), 404\u2013409 (2023)","journal-title":"Int. J. Pharm. Qual. Assur."},{"issue":"2","key":"4686_CR66","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/FJC.0000000000001299","volume":"80","author":"J Bucheit","year":"2022","unstructured":"J. Bucheit, J. Ayers, L. Pamulapati, A. Browning, E. Sisson, A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health. J. Cardiovasc. Pharmacol. 80(2), 171\u2013179 (2022)","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"1","key":"4686_CR67","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40360-024-00789-9","volume":"25","author":"Q Yang","year":"2024","unstructured":"Q. Yang, J. Wang, M. Wang, S. Zhang, Q.-Q.J.B.P. He, Toxicology, Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database. BMC Pharmacol. Toxicol. 25(1), 64 (2024)","journal-title":"BMC Pharmacol. Toxicol."},{"key":"4686_CR68","volume-title":"Tirzepatide Injection (Mounjaro) - Prescribing Information. Silver Spring, MD","author":"US Food","year":"2022","unstructured":"U.S. Food, A.F.D.A. Drug, Label, Tirzepatide Injection (Mounjaro) - Prescribing Information. Silver Spring, MD (Center for Drug Evaluation and Research (CDER), U.S. FDA, USA, 2022). 2022\/05\/13"},{"issue":"8","key":"4686_CR69","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s40262-021-01012-2","volume":"60","author":"S Urva","year":"2021","unstructured":"S. Urva, T. Quinlan, J. Landry, J. Martin, C. Loghin, Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clin. Pharmacokinet. 60(8), 1049\u20131059 (2021)","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"4686_CR70","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40262-022-01140-3","volume":"61","author":"S Urva","year":"2022","unstructured":"S. Urva, T. Quinlan, J. Landry, X. Ma, J.A. Martin, C.T. Benson, Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clin. Pharmacokinet. 61(7), 1057\u20131067 (2022)","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"4686_CR71","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/j.apsb.2022.11.008","volume":"13","author":"Y Xie","year":"2023","unstructured":"Y. Xie, Q. Zhou, Q. He, X. Wang, J. Wang, Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition. Acta Pharm. Sinica B 13(6), 2383\u20132402 (2023)","journal-title":"Acta Pharm. Sinica B"},{"issue":"2","key":"4686_CR72","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1210\/clinem\/dgad532","volume":"109","author":"GR Mullins","year":"2024","unstructured":"G.R. Mullins, M.E. Hodsdon, Y.G. Li, G. Anglin, S. Urva, K. Schneck et al., Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies. J. Clin. Endocrinol. Metab. 109(2), 361\u2013369 (2024)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4686_CR73","doi-asserted-by":"crossref","unstructured":"H.L. Heerspink, A. Friedman, P. Bjornstad, Van D. Raalte, D. Cao, L.-E. Garcia-Perez et al., 264-OR: Effect of Tirzepatide on Kidney Function in People with Excess Body Weight and Type 2 Diabetes\u2014A Post-Hoc Analysis of the SURMOUNT-2 Trial. Diabetes 2024;73(Supplement_1).264-OR.","DOI":"10.2337\/db24-264-OR"},{"issue":"4","key":"4686_CR74","first-page":"1","volume":"13","author":"ZA Mohammed","year":"2025","unstructured":"Z.A. Mohammed, M. Mohammed, R. Ali, N. Mohammed, 5\u00a0g and Ai in Wearable Medical Devices: A New Era of Preventive Healthcare. Ijireeice. 13(4), 1\u201311 (2025)","journal-title":"Ijireeice"},{"key":"4686_CR75","doi-asserted-by":"publisher","first-page":"171198","DOI":"10.1016\/j.peptides.2024.171198","volume":"176","author":"A Liskiewicz","year":"2024","unstructured":"A. Liskiewicz, T.D. Muller, Regulation of energy metabolism through central GIPR signaling. Peptides. 176, 171198 (2024)","journal-title":"Peptides"},{"issue":"1","key":"4686_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgae719","volume":"110","author":"RJ Jalleh","year":"2024","unstructured":"R.J. Jalleh, M.P. Plummer, C.S. Marathe, M.M. Umapathysivam, D.R. Quast, C.K. Rayner et al., Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J. Clin. Endocrinol. Metab. 110(1), 1\u201315 (2024)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"4686_CR77","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"L.J. Aronne, N. Sattar, D.B. Horn, H.E. Bays, S. Wharton, W.Y. Lin et al., Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 331(1), 38\u201348 (2024)","journal-title":"JAMA"},{"issue":"2","key":"4686_CR78","doi-asserted-by":"publisher","first-page":"e14660","DOI":"10.1111\/nmo.14660","volume":"36","author":"M Camilleri","year":"2024","unstructured":"M. Camilleri, The role of gastric function in control of food intake (and body weight) in relation to obesity, as well as pharmacological and surgical interventions. Neurogastroenterol Motil. 36(2), e14660 (2024)","journal-title":"Neurogastroenterol Motil."},{"issue":"5","key":"4686_CR79","doi-asserted-by":"publisher","first-page":"e70027","DOI":"10.1002\/prp2.70027","volume":"12","author":"GS Clarke","year":"2024","unstructured":"G.S. Clarke, A.J. Page, S. Eldeghaidy, The gut-brain axis in appetite, satiety, food intake, and eating behavior: Insights from animal models and human studies. Pharmacol. Res. Perspect. 12(5), e70027 (2024)","journal-title":"Pharmacol. Res. Perspect."},{"issue":"1","key":"4686_CR80","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tips.2022.11.001","volume":"44","author":"GA Boer","year":"2023","unstructured":"G.A. Boer, D.L. Hay, A. Tups, Obesity pharmacotherapy: incretin action in the central nervous system. Trends Pharmacol. Sci. 44(1), 50\u201363 (2023)","journal-title":"Trends Pharmacol. Sci."},{"issue":"9","key":"4686_CR81","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1038\/s41591-025-03774-9","volume":"31","author":"CK Martin","year":"2025","unstructured":"C.K. Martin, O.T. Carmichael, S. Carnell, R.V. Considine, D.A. Kareken, U. Dydak et al., Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat. Med. 31(9), 3141\u20133150 (2025)","journal-title":"Nat. Med."},{"issue":"21","key":"4686_CR82","doi-asserted-by":"publisher","first-page":"10741","DOI":"10.3390\/ijms262110741","volume":"26","author":"D Viana","year":"2025","unstructured":"D. Viana, A.L. Invitti, E. Schor, Tirzepatide as a Potential Disease-Modifying Therapy in Lipedema: A Narrative Review on Bridging Metabolism, Inflammation, and Fibrosis. Int. J. Mol. Sci. 26(21), 10741 (2025)","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"4686_CR83","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","volume":"19","author":"R Hammoud","year":"2023","unstructured":"R. Hammoud, D.J. Drucker, Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat. reviews Endocrinol. 19(4), 201\u2013216 (2023)","journal-title":"Nat. reviews Endocrinol."},{"issue":"1","key":"4686_CR84","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev-nutr-071812-161201","volume":"34","author":"MR Hayes","year":"2014","unstructured":"M.R. Hayes, E.G. Mietlicki-Baase, S.E. Kanoski, De B.C. Jonghe, Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose. Annu. Rev. Nutr. 34(1), 237\u2013260 (2014)","journal-title":"Annu. Rev. Nutr."},{"issue":"4","key":"4686_CR85","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s12276-021-00677-w","volume":"54","author":"HR Wachsmuth","year":"2022","unstructured":"H.R. Wachsmuth, S.N. Weninger, F.A. Duca, Role of the gut-brain axis in energy and glucose metabolism. Exp. Mol. Med. 54(4), 377\u2013392 (2022)","journal-title":"Exp. Mol. Med."},{"issue":"17","key":"4686_CR86","doi-asserted-by":"publisher","first-page":"9588","DOI":"10.3390\/ijms23179588","volume":"23","author":"P Zhang","year":"2022","unstructured":"P. Zhang, Influence of Foods and Nutrition on the Gut Microbiome and Implications for Intestinal Health. Int. J. Mol. Sci. 23(17), 9588 (2022)","journal-title":"Int. J. Mol. Sci."},{"key":"4686_CR87","doi-asserted-by":"publisher","first-page":"177827","DOI":"10.1016\/j.ejphar.2025.177827","volume":"1002","author":"R Wang","year":"2025","unstructured":"R. Wang, Z. Lin, M. He, Y. Liao, Y. Xu, C. Chen et al., The role of gut microbiota in Tirzepatide-mediated alleviation of high-fat diet-induced obesity. Eur. J. Pharmacol. 1002, 177827 (2025)","journal-title":"Eur. J. Pharmacol."},{"key":"4686_CR88","doi-asserted-by":"publisher","first-page":"113937","DOI":"10.1016\/j.intimp.2024.113937","volume":"147","author":"W Hu","year":"2025","unstructured":"W. Hu, W. Gong, F. Yang, R. Cheng, G. Zhang, L. Gan et al., Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice. Int. Immunopharmacol. 147, 113937 (2025)","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"4686_CR89","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3390\/ijms26031094","volume":"26","author":"E Mlynarska","year":"2025","unstructured":"E. Mlynarska, W. Czarnik, N. Dzieza, W. Jedraszak, G. Majchrowicz, F. Prusinowski et al., Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications. Int. J. Mol. Sci. 26(3), 1094 (2025)","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"4686_CR90","first-page":"843","volume":"15","author":"V Trapanese","year":"2025","unstructured":"V. Trapanese, A. Dagostino, M.R. Natale, F. Giofre, C. Vatalaro, M. Melina et al., Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies. Life (Basel). 15(6), 843 (2025)","journal-title":"Life (Basel)"},{"issue":"11","key":"4686_CR91","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/nu17111769","volume":"17","author":"Z Peng","year":"2025","unstructured":"Z. Peng, T. Hou, K. Yang, J. Zhang, Y.H. Mao, X. Hou, Microecologics and Exercise: Targeting the Microbiota-Gut-Brain Axis for Central Nervous System Disease Intervention. Nutrients. 17(11), 1769 (2025)","journal-title":"Nutrients"},{"key":"4686_CR92","doi-asserted-by":"publisher","first-page":"123310","DOI":"10.1016\/j.lfs.2024.123310","volume":"361","author":"FM Silva-Veiga","year":"2025","unstructured":"F.M. Silva-Veiga, T.S. Marinho, de V. Souza-Mello, M.B. Aguila, C.A. Mandarim-de-Lacerda, Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), positively impacts the altered microbiota of obese, diabetic, ovariectomized mice. Life Sci. 361, 123310 (2025)","journal-title":"Life Sci."},{"issue":"10","key":"4686_CR93","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3390\/microorganisms10102061","volume":"10","author":"N Abdalqadir","year":"2022","unstructured":"N. Abdalqadir, K. Adeli, GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk. Microorganisms. 10(10), 2061 (2022)","journal-title":"Microorganisms"},{"issue":"12","key":"4686_CR94","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1080\/17460441.2025.2579124","volume":"20","author":"SP Papadakos","year":"2025","unstructured":"S.P. Papadakos, C. Georgiadou, E. Kassi, R.I. Velliou, A. Chatzigeorgiou, Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery. Expert Opin. Drug Discov. 20(12), 1683\u20131700 (2025)","journal-title":"Expert Opin. Drug Discov"},{"issue":"10","key":"4686_CR95","doi-asserted-by":"publisher","first-page":"5375","DOI":"10.3390\/ijms22105375","volume":"22","author":"A Di","year":"2021","unstructured":"A. Di, S. Ciaula, H. Passarella, M. Shanmugam, L. Noviello, D.Q. Bonfrate, Wang et al., Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int. J. Mol. Sci. 22(10), 5375 (2021)","journal-title":"J. Mol. Sci."},{"issue":"10","key":"4686_CR96","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nri.2016.88","volume":"16","author":"ME Johansson","year":"2016","unstructured":"M.E. Johansson, G.C. Hansson, Immunological aspects of intestinal mucus and mucins. Nat. Rev. Immunol. 16(10), 639\u2013649 (2016)","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"4686_CR97","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","volume":"1","author":"A Gastaldelli","year":"2019","unstructured":"A. Gastaldelli, K. Cusi, From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep. 1(4), 312\u2013328 (2019)","journal-title":"JHEP Rep."},{"issue":"1","key":"4686_CR98","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Z. Zheng, Y. Zong, Y. Ma, Y. Tian, Y. Pang, C. Zhang et al., Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal. Transduct. Target. Ther. 9(1), 234 (2024)","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"2","key":"4686_CR99","doi-asserted-by":"publisher","first-page":"e2609","DOI":"10.1038\/cddis.2017.28","volume":"8","author":"M Yang","year":"2017","unstructured":"M. Yang, J. Wang, S. Wu, L. Yuan, X. Zhao, C. Liu et al., Duodenal GLP-1 signaling regulates hepatic glucose production through a PKC-delta-dependent neurocircuitry. Cell. Death Dis. 8(2), e2609 (2017)","journal-title":"Cell. Death Dis."},{"key":"4686_CR100","doi-asserted-by":"publisher","first-page":"646113","DOI":"10.3389\/fcell.2021.646113","volume":"9","author":"R Li","year":"2021","unstructured":"R. Li, X. Sun, P. Li, W. Li, L. Zhao, L. Zhu et al., GLP-1-Induced AMPK Activation Inhibits PARP-1 and Promotes LXR-Mediated ABCA1 Expression to Protect Pancreatic beta-Cells Against Cholesterol-Induced Toxicity Through Cholesterol Efflux. Front. Cell. Dev. Biol. 9, 646113 (2021)","journal-title":"Front. Cell. Dev. Biol."},{"issue":"9","key":"4686_CR101","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1111\/jgh.17037","volume":"40","author":"D Ezhilarasan","year":"2025","unstructured":"D. Ezhilarasan, Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key? J. Gastroenterol. Hepatol. 40(9), 2163\u20132175 (2025)","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"4686_CR102","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12944-024-02416-2","volume":"24","author":"J Liang","year":"2025","unstructured":"J. Liang, H. Liu, G. Lv, X. Chen, Z. Yang, K. Hu et al., Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics. Lipids Health Dis. 24(1), 8 (2025)","journal-title":"Lipids Health Dis."},{"issue":"7","key":"4686_CR103","doi-asserted-by":"publisher","first-page":"E770","DOI":"10.1152\/ajpendo.00523.2012","volume":"304","author":"W Chen","year":"2013","unstructured":"W. Chen, B. Chang, X. Wu, L. Li, M. Sleeman, L. Chan, Inactivation of Plin4 downregulates Plin5 and reduces cardiac lipid accumulation in mice. Am. J. Physiol. Endocrinol. metabolism. 304(7), E770\u2013E779 (2013)","journal-title":"Am. J. Physiol. Endocrinol. metabolism"},{"issue":"5","key":"4686_CR104","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cmet.2025.03.011","volume":"37","author":"E Ravussin","year":"2025","unstructured":"E. Ravussin, G. Sanchez-Delgado, C.K. Martin, R.A. Beyl, F.L. Greenway, L.S. O\u2019Farrell et al., Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation. Cell Metabol. 37(5), 1060\u201374e4 (2025)","journal-title":"Cell Metabol."},{"issue":"7922","key":"4686_CR105","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41586-022-05006-3","volume":"608","author":"JQ Wang","year":"2022","unstructured":"J.Q. Wang, L.L. Li, A. Hu, G. Deng, J. Wei, Y.F. Li et al., Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion. Nature. 608(7922), 413\u2013420 (2022)","journal-title":"Nature"},{"issue":"2","key":"4686_CR106","doi-asserted-by":"publisher","first-page":"102184","DOI":"10.1016\/j.omtn.2024.102184","volume":"35","author":"S Li","year":"2024","unstructured":"S. Li, F. Xiong, S. Zhang, J. Liu, G. Gao, J. Xie et al., Oligonucleotide therapies for nonalcoholic steatohepatitis. Mol. therapy Nucleic acids. 35(2), 102184 (2024)","journal-title":"Mol. therapy Nucleic acids"},{"issue":"23","key":"4686_CR107","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.3748\/wjg.v30.i23.2964","volume":"30","author":"J Rocho\u0144","year":"2024","unstructured":"J. Rocho\u0144, P. Kalinowski, K. Szymanek-Majchrzak, M. Gr\u0105t, Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease. World J. Gastroenterol. 30(23), 2964\u20132980 (2024)","journal-title":"World J. Gastroenterol."},{"key":"4686_CR108","doi-asserted-by":"publisher","first-page":"602574","DOI":"10.3389\/fcell.2020.602574","volume":"8","author":"Y Fang","year":"2020","unstructured":"Y. Fang, L. Ji, C. Zhu, Y. Xiao, J. Zhang, J. Lu et al., Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway. Front. Cell. Dev. Biol. 8, 602574 (2020)","journal-title":"Front. Cell. Dev. Biol."},{"issue":"3","key":"4686_CR109","first-page":"6","volume":"3","author":"AJ Alathary","year":"2024","unstructured":"A.J. Alathary, Z.J. Kadhim, Tirzepatide protects against hepatic oxidative stress in high-fat induced obesity in male rats. Maaen J. Med. Sci. 3(3), 6 (2024)","journal-title":"Maaen J. Med. Sci."},{"issue":"8","key":"4686_CR110","first-page":"908","volume":"14","author":"JS Hwang","year":"2025","unstructured":"J.S. Hwang, T.H. Lai, D.R. Kim, Targeting Lipophagy in Liver Diseases: Impact on Oxidative Stress and Steatohepatitis. Antioxid. (Basel Switzerland). 14(8), 908 (2025)","journal-title":"Antioxid. (Basel Switzerland)"},{"issue":"1","key":"4686_CR111","doi-asserted-by":"publisher","first-page":"49","DOI":"10.21037\/hbsn-24-464","volume":"14","author":"M Ammann","year":"2025","unstructured":"M. Ammann, J.P. Jonas, D. Pereyra, J. Santol, H. Hackl, T. Kalchbrenner et al., Plasma GLP-1 and metabolic dynamics during human liver regeneration and their association with posthepatectomy liver failure. Hepatobiliary Surg. Nutr. 14(1), 49\u201365 (2025)","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"7","key":"4686_CR112","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.3390\/ijms25073832","volume":"25","author":"LG Chrysavgis","year":"2024","unstructured":"L.G. Chrysavgis, S. Kazanas, K. Bafa, S. Rozani, M.E. Koloutsou, E. Cholongitas, Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature. Int. J. Mol. Sci. 25(7), 3832 (2024)","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"4686_CR113","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1111\/apt.70196","volume":"61","author":"M Zafer","year":"2025","unstructured":"M. Zafer, F. Tavaglione, M. Romero-G\u00f3mez, R. Loomba, Review Article, GLP-1 Receptor Agonists and Glucagon\/GIP\/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD. Aliment. Pharmacol. Ther. 61(12), 1872\u20131888 (2025)","journal-title":"Aliment. Pharmacol. Ther."},{"key":"4686_CR114","doi-asserted-by":"publisher","first-page":"1675552","DOI":"10.3389\/fphar.2025.1675552","volume":"16","author":"B Gong","year":"2025","unstructured":"B. Gong, C. Li, Z. Shi, F. Wang, R. Dai, G. Chen et al., GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy. Front. Pharmacol. 16, 1675552 (2025)","journal-title":"Front. Pharmacol."},{"issue":"1","key":"4686_CR115","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12933-023-01940-2","volume":"22","author":"S Sachs","year":"2023","unstructured":"S. Sachs, A. Gotz, B. Finan, A. Feuchtinger, R.D. DiMarchi, Y. Doring et al., GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease. Cardiovasc. Diabetol. 22(1), 217 (2023)","journal-title":"Cardiovasc. Diabetol."},{"issue":"8","key":"4686_CR116","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11883-019-0791-9","volume":"21","author":"MR Taskinen","year":"2019","unstructured":"M.R. Taskinen, C.J. Packard, J. Boren, Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD. Curr. Atheroscler. Rep. 21(8), 27 (2019)","journal-title":"Curr. Atheroscler. Rep."},{"issue":"12","key":"4686_CR117","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1111\/dom.14174","volume":"22","author":"JM Wilson","year":"2020","unstructured":"J.M. Wilson, A. Nikooienejad, D.A. Robins, W.C. Roell, J.S. Riesmeyer, A. Haupt et al., The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes. Metab. 22(12), 2451\u20132459 (2020)","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"4686_CR118","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","volume":"21","author":"MA Nauck","year":"2022","unstructured":"M.A. Nauck, D.A. D\u2019Alessio, Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc. Diabetol. 21(1), 169 (2022)","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"4686_CR119","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11154-025-09991-4","volume":"27","author":"W Masson","year":"2026","unstructured":"W. Masson, M. Lobo, J.P. Nogueira, L. Barbagelata, P. Touzas, J.P. Frias, Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis. Reviews Endocr. metabolic disorders. 27(1), 5\u201315 (2026)","journal-title":"Reviews Endocr. metabolic disorders"},{"issue":"2","key":"4686_CR120","first-page":"97","volume":"21","author":"FN Varra","year":"2025","unstructured":"F.N. Varra, M. Varras, V.K. Varra, P. Theodosis-Nobelos, Anti-obesity Treatments with Anti-inflammatory and Antioxidant Potential and their Effects on Obesity-related Metabolic and Cardiovascular Disorders: A Narrative Review. Curr. Rev. Clin. Exp. Pharmacol. 21(2), 97\u2013116 (2025)","journal-title":"Curr. Rev. Clin. Exp. Pharmacol."},{"issue":"6","key":"4686_CR121","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3390\/pharmaceutics16060693","volume":"16","author":"A Lymperopoulos","year":"2024","unstructured":"A. Lymperopoulos, J.I. Borges, R.A. Stoicovy, Cyclic Adenosine Monophosphate in Cardiac and Sympathoadrenal GLP-1 Receptor Signaling: Focus on Anti-Inflammatory Effects. Pharmaceutics. 16(6), 693 (2024)","journal-title":"Pharmaceutics"},{"issue":"5","key":"4686_CR122","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.62347\/ZWSR4476","volume":"17","author":"M Wan","year":"2025","unstructured":"M. Wan, W. Zhao, Y. Cai, Q. He, J. Zeng, Role of gut-brain axis dysregulation in the pathogenesis of non-alcoholic fatty liver disease: mechanisms and therapeutic implications. Am. J. Transl Res. 17(5), 3276\u20133292 (2025)","journal-title":"Am. J. Transl Res."},{"issue":"32","key":"4686_CR123","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.4254\/wjh.v8.i32.1354","volume":"8","author":"S Kiziltas","year":"2016","unstructured":"S. Kiziltas, Toll-like receptors in pathophysiology of liver diseases. World J. Hepatol. 8(32), 1354\u20131369 (2016)","journal-title":"World J. Hepatol."},{"issue":"9","key":"4686_CR124","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/17512433.2025.2559907","volume":"18","author":"T Koufakis","year":"2025","unstructured":"T. Koufakis, D. Patoulias, M. Apostolopoulou, P. Georgianos, D.S. Popovic, Dual incretin agonism and the gut microbiome: does the heart of metabolic regulation beat in the gut? Expert Rev. Clin. Pharmacol. 18(9), 625\u2013627 (2025)","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"7","key":"4686_CR125","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/oby.2006.129","volume":"14","author":"L Getty-Kaushik","year":"2006","unstructured":"L. Getty-Kaushik, D.H. Song, M.O. Boylan, B.E. Corkey, M.M. Wolfe, Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification. Obes. (Silver Spring Md). 14(7), 1124\u20131131 (2006)","journal-title":"Obes. (Silver Spring Md)"},{"issue":"1","key":"4686_CR126","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s13679-025-00660-w","volume":"14","author":"F Villarroya","year":"2025","unstructured":"F. Villarroya, M. Peyrou, M. Giralt, Adipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs. Curr. Obes. Rep. 14(1), 67 (2025)","journal-title":"Curr. Obes. Rep."},{"issue":"11","key":"4686_CR127","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1210\/en.2011-1070","volume":"152","author":"J Vendrell","year":"2011","unstructured":"J. Vendrell, El R. Bekay, B. Peral, E. Garcia-Fuentes, A. Megia, M. Macias-Gonzalez et al., Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology. 152(11), 4072\u20134079 (2011)","journal-title":"Endocrinology"},{"issue":"3","key":"4686_CR128","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4093\/dmj.2023.0277","volume":"48","author":"T Bu","year":"2024","unstructured":"T. Bu, Z. Sun, Y. Pan, X. Deng, G. Yuan, Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism. Diabetes metabolism J. 48(3), 354\u2013372 (2024)","journal-title":"Diabetes metabolism J."},{"issue":"5","key":"4686_CR129","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00125-016-3896-5","volume":"59","author":"F Xu","year":"2016","unstructured":"F. Xu, B. Lin, X. Zheng, Z. Chen, H. Cao, H. Xu et al., GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1. Diabetologia. 59(5), 1059\u20131069 (2016)","journal-title":"Diabetologia"},{"issue":"5","key":"4686_CR130","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.3390\/cells10051122","volume":"10","author":"JI van der Vaart","year":"2021","unstructured":"van der J.I. Vaart, M.R. Boon, R.H. Houtkooper, The Role of AMPK Signaling in Brown Adipose Tissue Activation. Cells. 10(5), 1122 (2021)","journal-title":"Cells"},{"issue":"10","key":"4686_CR131","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11892-018-1049-6","volume":"18","author":"EM Desjardins","year":"2018","unstructured":"E.M. Desjardins, G.R. Steinberg, Emerging Role of AMPK in Brown and Beige Adipose Tissue (BAT): Implications for Obesity, Insulin Resistance, and Type 2 Diabetes. Curr. Diab Rep. 18(10), 80 (2018)","journal-title":"Curr. Diab Rep."},{"issue":"9","key":"4686_CR132","doi-asserted-by":"publisher","first-page":"e70091","DOI":"10.1111\/apha.70091","volume":"241","author":"AS Muralikrishnan","year":"2025","unstructured":"A.S. Muralikrishnan, V. Biasin, D. Zabini, E. Osto, Immune and Vascular Function in Cardiometabolic Disorders: Interplay With Sex Differences and Impact on Incretin Therapy. Acta Physiol. (Oxf). 241(9), e70091 (2025)","journal-title":"Acta Physiol. (Oxf)"},{"issue":"7","key":"4686_CR133","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/biomedicines12071398","volume":"12","author":"G Marroncini","year":"2024","unstructured":"G. Marroncini, L. Naldi, S. Martinelli, A. Amedei, Gut-Liver-Pancreas Axis Crosstalk in Health and Disease: From the Role of Microbial Metabolites to Innovative Microbiota Manipulating Strategies. Biomedicines. 12(7), 1398 (2024)","journal-title":"Biomedicines"},{"issue":"5","key":"4686_CR134","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2337\/dc22-1710","volume":"46","author":"T Heise","year":"2023","unstructured":"T. Heise, J.H. DeVries, S. Urva, J. Li, E.J. Pratt, M.K. Thomas et al., Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care. 46(5), 998\u20131004 (2023)","journal-title":"Diabetes Care"},{"issue":"3","key":"4686_CR135","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/fbe2.12098","volume":"3","author":"S Jain","year":"2024","unstructured":"S. Jain, A.K. Shukla, S. Deepika, Panwar, A. Kumari, A.K. Yadav et al., Revolutionizing disease treatment through bioengineered probiotics and glucagon-like peptide 1 (GLP\u20101) based strategies: A path towards effective cures. Food Bioeng. 3(3), 280\u2013300 (2024)","journal-title":"Food Bioeng."},{"key":"4686_CR136","doi-asserted-by":"publisher","first-page":"116342","DOI":"10.1016\/j.ejmech.2024.116342","volume":"269","author":"B Gong","year":"2024","unstructured":"B. Gong, Z. Yao, C. Zhou, W. Wang, L. Sun, J. Han, Glucagon-like peptide-1 analogs: Miracle drugs are blooming? Eur. J. Med. Chem. 269, 116342 (2024)","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"4686_CR137","doi-asserted-by":"publisher","first-page":"240303","DOI":"10.1098\/rsob.240303","volume":"15","author":"V Kumar","year":"2025","unstructured":"V. Kumar, GLP-1\/GLP-1R axis: from metabolism (obesity and T2DM) to immunity. Open. biology. 15(7), 240303 (2025)","journal-title":"Open. biology"},{"issue":"1","key":"4686_CR138","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12967-024-04927-z","volume":"22","author":"RA Fontanella","year":"2024","unstructured":"R.A. Fontanella, P. Ghosh, A. Pesapane, F. Taktaz, A. Puocci, M. Franzese et al., Tirzepatide prevents neurodegeneration through multiple molecular pathways. J. translational Med. 22(1), 114 (2024)","journal-title":"J. translational Med."},{"issue":"11","key":"4686_CR139","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1515\/hsz-2020-0195","volume":"401","author":"A English","year":"2020","unstructured":"A. English, S.L. Craig, P.R. Flatt, N. Irwin, Individual and combined effects of GIP and xenin on differentiation, glucose uptake and lipolysis in 3T3-L1 adipocytes. Biol. Chem. 401(11), 1293\u20131303 (2020)","journal-title":"Biol. Chem."},{"issue":"4","key":"4686_CR140","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1194\/jlr.M012203","volume":"52","author":"SJ Kim","year":"2011","unstructured":"S.J. Kim, C. Nian, C.H. McIntosh, Adipocyte expression of the glucose-dependent insulinotropic polypeptide receptor involves gene regulation by PPARgamma and histone acetylation. J. Lipid Res. 52(4), 759\u2013770 (2011)","journal-title":"J. Lipid Res."},{"key":"4686_CR141","doi-asserted-by":"publisher","first-page":"177979","DOI":"10.1016\/j.ejphar.2025.177979","volume":"1003","author":"GH Alshehri","year":"2025","unstructured":"G.H. Alshehri, H.M. Al-Kuraishy, A.I. Al-Gareeb, M.N. Fawzy, H.J. Waheed, M. Papadakis et al., A novel therapeutic prospect: a dual-acting tirzepatide for Alzheimer\u2019s disease. Eur. J. Pharmacol. 1003, 177979 (2025)","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"4686_CR142","first-page":"299","volume":"13","author":"D Rathakrishnan","year":"2024","unstructured":"D. Rathakrishnan, V.A.G. Sundari, S. Sahay, S. MI, DK, M. George, A Narrative Review on Clinical Evidence of Tirzepatide\u2019s Role in Addressing Type 2 Diabetes and Obesity Management. Clin. Diabetol. 13(5), 299\u2013306 (2024)","journal-title":"Clin. Diabetol."},{"issue":"1","key":"4686_CR143","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cmet.2024.11.003","volume":"37","author":"X Yu","year":"2025","unstructured":"X. Yu, S. Chen, J.B. Funcke, L.G. Straub, V. Pirro, M.P. Emont et al., The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice. Cell. Metab. 37(1), 187\u2013204 (2025). e7","journal-title":"Cell. Metab."},{"issue":"8","key":"4686_CR144","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1172\/JCI86610","volume":"126","author":"PL Gordts","year":"2016","unstructured":"P.L. Gordts, R. Nock, N.H. Son, B. Ramms, I. Lew, J.C. Gonzales et al., ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J. Clin. Investig. 126(8), 2855\u20132866 (2016)","journal-title":"J. Clin. Investig."},{"issue":"Pt 2","key":"4686_CR145","doi-asserted-by":"publisher","first-page":"113499","DOI":"10.1016\/j.intimp.2024.113499","volume":"143","author":"Y Xia","year":"2024","unstructured":"Y. Xia, J. Jin, Y. Sun, X. Kong, Z. Shen, R. Yan et al., Tirzepatide\u2019s role in targeting adipose tissue macrophages to reduce obesity-related inflammation and improve insulin resistance. Int. Immunopharmacol. 143(Pt 2), 113499 (2024)","journal-title":"Int. Immunopharmacol."},{"key":"4686_CR146","doi-asserted-by":"publisher","first-page":"1402583","DOI":"10.3389\/fendo.2024.1402583","volume":"15","author":"S Corrao","year":"2024","unstructured":"S. Corrao, C. Pollicino, D. Maggio, A. Torres, C. Argano, Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence. Front. Endocrinol. (Lausanne). 15, 1402583 (2024)","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"4686_CR147","doi-asserted-by":"publisher","first-page":"101550","DOI":"10.1016\/j.molmet.2022.101550","volume":"64","author":"RJ Samms","year":"2022","unstructured":"R.J. Samms, G. Zhang, W. He, O. Ilkayeva, B.A. Droz, S.M. Bauer et al., Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue. Mol. Metab. 64, 101550 (2022)","journal-title":"Mol. Metab."},{"key":"4686_CR148","doi-asserted-by":"publisher","first-page":"101550","DOI":"10.1016\/j.molmet.2022.101550","volume":"64","author":"RJ Samms","year":"2022","unstructured":"R.J. Samms, G. Zhang, W. He, O. Ilkayeva, B.A. Droz, S.M. Bauer et al., Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue. Mol. metabolism. 64, 101550 (2022)","journal-title":"Mol. metabolism"},{"issue":"5","key":"4686_CR149","doi-asserted-by":"publisher","first-page":"bvad056","DOI":"10.1210\/jendso\/bvad056","volume":"7","author":"CJ Lee","year":"2023","unstructured":"C.J. Lee, H. Mao, V.T. Thieu, L.F. Land\u00f3, M.K. Thomas, Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1). J. Endocr. Soc. 7(5), bvad056 (2023)","journal-title":"J. Endocr. Soc."},{"issue":"12","key":"4686_CR150","first-page":"1650","volume":"14","author":"M Barac","year":"2025","unstructured":"M. Barac, J. Roganovic, GLP-1 Receptor Signaling and Oral Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects. Biology (Basel). 14(12), 1650 (2025)","journal-title":"Biology (Basel)"},{"issue":"1","key":"4686_CR151","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3390\/ijms26010421","volume":"26","author":"EG Gojani","year":"2025","unstructured":"E.G. Gojani, B. Wang, D. Li, O. Kovalchuk, I. Kovalchuk, Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on beta-Cell Maintenance and Function Under High-Glucose-High-Lipid Conditions: A Comparative Study. Int. J. Mol. Sci. 26(1), 421 (2025)","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"4686_CR152","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/ph18050614","volume":"18","author":"M Urkon","year":"2025","unstructured":"M. Urkon, E. Ferencz, J.A. Szasz, M.I.M. Szabo, K. Orban-Kis, S. Szatmari et al., Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer\u2019s Disease. Pharmaceuticals (Basel). 18(5), 614 (2025)","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"4686_CR153","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1021\/acs.biochem.4c00867","volume":"64","author":"L Liu","year":"2025","unstructured":"L. Liu, M. Rashid, J. Wess, Regulation of GLP-1 and Glucagon Receptor Function by beta-Arrestins in Metabolically Important Cell Types. Biochemistry. 64(5), 978\u2013986 (2025)","journal-title":"Biochemistry"},{"issue":"5","key":"4686_CR154","first-page":"e38379","volume":"15","author":"P Dutta","year":"2023","unstructured":"P. Dutta, Y. Kumar, A.T. Babu, S. Giri Ravindran, A. Salam, B. Rai et al., Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond. Cureus. 15(5), e38379 (2023)","journal-title":"Cureus"},{"issue":"1","key":"4686_CR155","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/14656566.2024.2436595","volume":"26","author":"M Hamza","year":"2025","unstructured":"M. Hamza, D. Papamargaritis, M.J. Davies, Tirzepatide for overweight and obesity management. Expert Opin. Pharmacother. 26(1), 31\u201349 (2025)","journal-title":"Expert Opin. Pharmacother."},{"issue":"9","key":"4686_CR156","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/13543784.2025.2546812","volume":"34","author":"S Fiorucci","year":"2025","unstructured":"S. Fiorucci, G. Urbani, Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives. Expert Opin. Investig. Drugs. 34(9), 655\u2013663 (2025)","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"5","key":"4686_CR157","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1111\/dom.16294","volume":"27","author":"A Zhang","year":"2025","unstructured":"A. Zhang, Q. Liu, Y. Xiong, J. Li, Y. Xu, H. Song et al., Tirzepatide reduces body weight by increasing fat utilization via the central nervous system-adipose tissue axis in male mice. Diabetes Obes. Metab. 27(5), 2844\u20132856 (2025)","journal-title":"Diabetes Obes. Metab."},{"key":"4686_CR158","doi-asserted-by":"publisher","first-page":"171117","DOI":"10.1016\/j.peptides.2023.171117","volume":"171","author":"G Pacini","year":"2024","unstructured":"G. Pacini, B. Ahren, The dual incretin co-agonist tirzepatide increases both insulin secretion and glucose effectiveness in model experiments in mice. Peptides. 171, 171117 (2024)","journal-title":"Peptides"},{"issue":"5","key":"4686_CR159","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/14656566.2023.2192865","volume":"24","author":"RA Lafferty","year":"2023","unstructured":"R.A. Lafferty, P.R. Flatt, N. Irwin, GLP-1\/GIP analogs: potential impact in the landscape of obesity pharmacotherapy. Expert Opin. Pharmacother. 24(5), 587\u2013597 (2023)","journal-title":"Expert Opin. Pharmacother"},{"issue":"17","key":"4686_CR160","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.3390\/ijms20174092","volume":"20","author":"DS Mathiesen","year":"2019","unstructured":"D.S. Mathiesen, J.I. Bagger, N.C. Bergmann, A. Lund, M.B. Christensen, T. Vilsboll et al., The Effects of Dual GLP-1\/GIP Receptor Agonism on Glucagon Secretion-A Review. Int. J. Mol. Sci. 20(17), 4092 (2019)","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"4686_CR161","doi-asserted-by":"publisher","first-page":"C74","DOI":"10.1152\/ajpcell.00474.2023","volume":"327","author":"R Bauri","year":"2024","unstructured":"R. Bauri, S. Bele, J. Edelli, N.C. Reddy, S. Kurukuti, T. Devasia et al., Reduced incretin receptor trafficking upon activation enhances glycemic control and reverses obesity in diet-induced obese mice. Am. J. Physiol. Cell. Physiol. 327(1), C74\u2013C96 (2024)","journal-title":"Am. J. Physiol. Cell. Physiol."},{"issue":"1","key":"4686_CR162","first-page":"29","volume":"12","author":"MC Pelle","year":"2021","unstructured":"M.C. Pelle, M. Provenzano, I. Zaffina, R. Pujia, F. Giofre, S. Luca et al., Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)\/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment. Life (Basel). 12(1), 29 (2021)","journal-title":"Life (Basel)"},{"issue":"1","key":"4686_CR163","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12982-024-00200-2","volume":"21","author":"S Sweta, Gupta","year":"2024","unstructured":"S. Sweta, Gupta, S. Bansal, S. Devi, S. Sharma, Laxmi et al., Tirzepatide a novel anti diabetic molecule unfold dual action. Discover Public. Health. 21(1), 75 (2024)","journal-title":"Discover Public. Health"},{"key":"4686_CR164","doi-asserted-by":"publisher","first-page":"101121","DOI":"10.1016\/j.jbior.2025.101121","volume":"99","author":"P Troster","year":"2026","unstructured":"P. Troster, M. Visa, P.O. Berggren, Alpha-to-beta cell crosstalk: Adaptive mechanisms shaping islet function. Adv. Biol. Regul. 99, 101121 (2026)","journal-title":"Adv. Biol. Regul."},{"issue":"Supplement 1","key":"4686_CR165","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.4103\/jod.jod_97_23","volume":"14","author":"OJ Lakhani","year":"2023","unstructured":"O.J. Lakhani, Alpha cells as targets for incretin therapy. J. Diabetol. 14(Supplement 1), S19\u2013S24 (2023)","journal-title":"J. Diabetol."},{"key":"4686_CR166","doi-asserted-by":"publisher","first-page":"920541","DOI":"10.3389\/fendo.2022.920541","volume":"13","author":"G Lisco","year":"2022","unstructured":"G. Lisco, De A. Tullio, O. Disoteo, De V. Geronimo, G. Piazzolla, De G. Pergola et al., Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis. Front. Endocrinol. (Lausanne). 13, 920541 (2022)","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"6","key":"4686_CR167","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s42255-023-00811-0","volume":"5","author":"K El","year":"2023","unstructured":"K. El, J.D. Douros, F.S. Willard, A. Novikoff, A. Sargsyan, D. Perez-Tilve et al., The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nat. Metab. 5(6), 945\u2013954 (2023)","journal-title":"Nat. Metab."},{"issue":"1","key":"4686_CR168","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12933-024-02319-7","volume":"23","author":"F Taktaz","year":"2024","unstructured":"F. Taktaz, R.A. Fontanella, L. Scisciola, A. Pesapane, M.G. Basilicata, P. Ghosh et al., Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide. Cardiovasc. Diabetol. 23(1), 242 (2024)","journal-title":"Cardiovasc. Diabetol."},{"issue":"21","key":"4686_CR169","doi-asserted-by":"publisher","first-page":"e2032232024","DOI":"10.1523\/JNEUROSCI.2032-23.2024","volume":"44","author":"XY Xu","year":"2024","unstructured":"X.Y. Xu, J.X. Wang, J.L. Chen, M. Dai, Y.M. Wang, Q. Chen et al., GLP-1 in the Hypothalamic Paraventricular Nucleus Promotes Sympathetic Activation and Hypertension. J. neuroscience: official J. Soc. Neurosci. 44(21), e2032232024 (2024)","journal-title":"J. neuroscience: official J. Soc. Neurosci."},{"issue":"6","key":"4686_CR170","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","volume":"138","author":"A Moiz","year":"2025","unstructured":"A. Moiz, K.B. Filion, M.A. Tsoukas, O.H. Yu, T.M. Peters, M.J. Eisenberg, Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. Am. J. Med. 138(6), 934\u2013940 (2025)","journal-title":"Am. J. Med."},{"issue":"5","key":"4686_CR171","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1021\/acschemneuro.4c00729","volume":"16","author":"P Delvadia","year":"2025","unstructured":"P. Delvadia, V. Dhote, A.S. Mandloi, R. Soni, J. Shah, Dual GLP-1 and GIP Agonist Tirzepatide Exerted Neuroprotective Action in a Parkinson\u2019s Disease Rat Model. ACS Chem. Neurosci. 16(5), 818\u2013825 (2025)","journal-title":"ACS Chem. Neurosci."},{"key":"4686_CR172","doi-asserted-by":"publisher","first-page":"106219","DOI":"10.1016\/j.ebiom.2026.106219","volume":"126","author":"CE Edvardsson","year":"2026","unstructured":"C.E. Edvardsson, X. Zhang, T.A. Emous, L. Adermark, S. Witley, M. Ericson et al., Tirzepatide attenuates mesolimbic cocaine-evoked dopamine levels and reduces cocaine taking, motivation and seeking behaviours in male rodents. EBioMedicine. 126, 106219 (2026)","journal-title":"EBioMedicine"},{"key":"4686_CR173","doi-asserted-by":"publisher","first-page":"106257","DOI":"10.1016\/j.ebiom.2026.106257","volume":"127","author":"LA Knackstedt","year":"2026","unstructured":"L.A. Knackstedt, Novel evidence for tirzepatide, a dual GLP-1\/GIP receptor agonist, to reduce the motivation for cocaine in rodents. EBioMedicine. 127, 106257 (2026)","journal-title":"EBioMedicine"},{"issue":"4","key":"4686_CR174","first-page":"664","volume":"61","author":"AM Patti","year":"2025","unstructured":"A.M. Patti, R.V. Giglio, M. Ciaccio, A.P. Stoian, T. Salmen, I.C. Bica et al., New Frontiers in Nutritional and Therapeutic Interventions for Obesity Phenotypes. Med. (Kaunas). 61(4), 664 (2025)","journal-title":"Med. (Kaunas)"},{"key":"4686_CR175","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.pcad.2024.12.010","volume":"89","author":"JH O\u2019Keefe","year":"2025","unstructured":"J.H. O\u2019Keefe, W.G. Franco, E.L. O\u2019Keefe, Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy. Prog Cardiovasc. Dis. 89, 102\u2013112 (2025)","journal-title":"Prog Cardiovasc. Dis."},{"key":"4686_CR176","doi-asserted-by":"publisher","first-page":"114238","DOI":"10.1016\/j.biopha.2023.114238","volume":"159","author":"AMA Mahmoud","year":"2023","unstructured":"A.M.A. Mahmoud, E.M. Mantawy, S.A. Wahdan, R.M. Ammar, E. El-Demerdash, Vildagliptin restores cognitive function and mitigates hippocampal neuronal apoptosis in cisplatin-induced chemo-brain: Imperative roles of AMPK\/Akt\/CREB\/ BDNF signaling cascades. Biomed. Pharmacother. 159, 114238 (2023)","journal-title":"Biomed. Pharmacother"},{"key":"4686_CR177","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3897\/pharmacia.72.e155150","volume":"72","author":"M Hristov","year":"2025","unstructured":"M. Hristov, G. Cheema, H. Ali, P. Andreeva-Gateva, Beyond glycemic control: the neuroprotective potential of tirzepatide. Pharmacia. 72, 1\u201310 (2025)","journal-title":"Pharmacia"},{"issue":"8","key":"4686_CR178","doi-asserted-by":"publisher","first-page":"e18491","DOI":"10.1016\/j.heliyon.2023.e18491","volume":"9","author":"Q Ma","year":"2023","unstructured":"Q. Ma, L. Wang, X.X. Liu, Z.G. An, X. Luo, L.L. Zhang et al., GLP-1 plays a protective role in hippocampal neuronal cells by activating cAMP-CREB-BDNF signaling pathway against CORT\u2009+\u2009HG-induced toxicity. Heliyon. 9(8), e18491 (2023)","journal-title":"Heliyon"},{"key":"4686_CR179","doi-asserted-by":"publisher","first-page":"171271","DOI":"10.1016\/j.peptides.2024.171271","volume":"179","author":"S Yang","year":"2024","unstructured":"S. Yang, X. Zhao, Y. Zhang, Q. Tang, Y. Li, Y. Du et al., Tirzepatide shows neuroprotective effects via regulating brain glucose metabolism in APP\/PS1 mice. Peptides. 179, 171271 (2024)","journal-title":"Peptides"},{"issue":"4","key":"4686_CR180","doi-asserted-by":"publisher","first-page":"E559","DOI":"10.1152\/ajpendo.00036.2019","volume":"317","author":"F Raka","year":"2019","unstructured":"F. Raka, S. Farr, J. Kelly, A. Stoianov, K. Adeli, Metabolic control via nutrient-sensing mechanisms: role of taste receptors and the gut-brain neuroendocrine axis. Am. J. Physiol. Endocrinol. Metab. 317(4), E559\u2013E72 (2019)","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"4686_CR181","doi-asserted-by":"publisher","first-page":"1532076","DOI":"10.3389\/fendo.2025.1532076","volume":"16","author":"PP James-Okoro","year":"2025","unstructured":"P.P. James-Okoro, J.E. Lewis, F.M. Gribble, F. Reimann, The role of GIPR in food intake control. Front. Endocrinol. (Lausanne). 16, 1532076 (2025)","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"9","key":"4686_CR182","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.2337\/dbi21-0001","volume":"70","author":"M Fukuda","year":"2021","unstructured":"M. Fukuda, The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity. Diabetes. 70(9), 1929\u20131937 (2021)","journal-title":"Diabetes"},{"key":"4686_CR183","doi-asserted-by":"publisher","first-page":"112308","DOI":"10.1016\/j.intimp.2024.112308","volume":"135","author":"NF Hassan","year":"2024","unstructured":"N.F. Hassan, D. Ragab, S.G. Ibrahim, M.M. Abd El-Galil, A. Hassan Abd-El-Hamid, D.M. Hamed et al., The potential role of Tirzepatide as adjuvant therapy in countering colistin-induced nephro and neurotoxicity in rats via modulation of PI3K\/p-Akt\/GSK3-beta\/NF-kB p65 hub, shielding against oxidative and endoplasmic reticulum stress, and activation of p-CREB\/BDNF\/TrkB cascade. Int. Immunopharmacol. 135, 112308 (2024)","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"4686_CR184","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s12020-024-04013-w","volume":"87","author":"J Ma","year":"2025","unstructured":"J. Ma, Y. Liu, J. Hu, X. Liu, Y. Xia, W. Xia et al., Tirzepatide administration improves cognitive impairment in HFD mice by regulating the SIRT3-NLRP3 axis. Endocrine. 87(2), 486\u2013497 (2025)","journal-title":"Endocrine"},{"key":"4686_CR185","doi-asserted-by":"publisher","first-page":"115443","DOI":"10.1016\/j.intimp.2025.115443","volume":"165","author":"R Tian","year":"2025","unstructured":"R. Tian, K. Liu, H. Lai, C. Liao, J. Li, H. Tu, GLP-1\/GIP dual agonist tirzepatide alleviates mice model of Parkinson\u2019s disease by promoting mitochondrial homeostasis. Int. Immunopharmacol. 165, 115443 (2025)","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"4686_CR186","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2337\/dbi21-0002","volume":"70","author":"RJ Samms","year":"2021","unstructured":"R.J. Samms, K.W. Sloop, F.M. Gribble, F. Reimann, A.E. Adriaenssens, GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Based Therapies in Treating Metabolic Disorders. Diabetes. 70(9), 1938\u20131944 (2021)","journal-title":"Diabetes"},{"issue":"24","key":"4686_CR187","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"A.M. Lincoff, K. Brown-Frandsen, H.M. Colhoun, J. Deanfield, S.S. Emerson, S. Esbjerg et al., Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl. J. Med. 389(24), 2221\u20132232 (2023)","journal-title":"N Engl. J. Med."},{"issue":"10516","key":"4686_CR188","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","volume":"406","author":"J Deanfield","year":"2025","unstructured":"J. Deanfield, A.M. Lincoff, S.E. Kahn, S.S. Emerson, I. Lingvay, B.M. Scirica et al., Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 406(10516), 2257\u20132268 (2025)","journal-title":"Lancet"},{"issue":"15","key":"4686_CR189","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1016\/j.cell.2024.06.003","volume":"187","author":"CM Kusminski","year":"2024","unstructured":"C.M. Kusminski, D. Perez-Tilve, T.D. Muller, R.D. DiMarchi, M.H. Tschop, P.E. Scherer, Transforming obesity: The advancement of multi-receptor drugs. Cell. 187(15), 3829\u20133853 (2024)","journal-title":"Cell"},{"issue":"5","key":"4686_CR190","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"M. Packer, M.R. Zile, C.M. Kramer, S.J. Baum, S.E. Litwin, V. Menon et al., Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl. J. Med. 392(5), 427\u2013437 (2025)","journal-title":"N Engl. J. Med."},{"issue":"6","key":"4686_CR191","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3390\/pharmaceutics16060693","volume":"16","author":"Lymperopoulos A","year":"2024","unstructured":"A. Lymperopoulos, J.I. Borges, R.A. Stoicovy. Cyclic Adenosine Monophosphate in Cardiac and Sympathoadrenal GLP-1 Receptor Signaling: Focus on Anti-Inflammatory Effects. Pharmaceutics. 16(6), 693 (2024)","journal-title":"Pharmaceutics"},{"issue":"8","key":"4686_CR192","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.7150\/ijbs.59965","volume":"17","author":"X Ma","year":"2021","unstructured":"X. Ma, Z. Liu, I. Ilyas, P.J. Little, D. Kamato, A. Sahebka et al., GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int. J. Biol. Sci. 17(8), 2050\u20132068 (2021)","journal-title":"Int. J. Biol. Sci."},{"issue":"3","key":"4686_CR193","doi-asserted-by":"publisher","first-page":"213","DOI":"10.12997\/jla.2023.12.3.213","volume":"12","author":"YK Cho","year":"2023","unstructured":"Y.K. Cho, La Y. Lee, C.H. Jung, The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist. J. Lipid Atheroscler. 12(3), 213\u2013222 (2023)","journal-title":"J. Lipid Atheroscler"},{"key":"4686_CR194","doi-asserted-by":"publisher","first-page":"110311","DOI":"10.1016\/j.intimp.2023.110311","volume":"120","author":"Q Liu","year":"2023","unstructured":"Q. Liu, J. Zhu, B. Kong, W. Shuai, H. Huang, Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4\/NF-kB\/NLRP3 pathway. Int. Immunopharmacol. 120, 110311 (2023)","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"4686_CR195","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","volume":"31","author":"BA Borlaug","year":"2025","unstructured":"B.A. Borlaug, M.R. Zile, C.M. Kramer, S.J. Baum, K. Hurt, S.E. Litwin et al., Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat. Med. 31(2), 544\u2013551 (2025)","journal-title":"Nat. Med."},{"issue":"5","key":"4686_CR196","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1007\/s10787-024-01556-2","volume":"32","author":"A Satheesan","year":"2024","unstructured":"A. Satheesan, J. Kumar, K.V. Leela, R. Murugesan, V. Chaithanya, M. Angelin, Review on the role of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome pathway in diabetes: mechanistic insights and therapeutic implications. Inflammopharmacology. 32(5), 2753\u20132779 (2024)","journal-title":"Inflammopharmacology"},{"issue":"16","key":"4686_CR197","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.3390\/jcm13164674","volume":"13","author":"R Le","year":"2024","unstructured":"R. Le, M.T. Nguyen, M.A. Allahwala, J.P. Psaltis, C.S. Marathe, J.A. Marathe et al., Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs. J. Clin. Med. 13(16), 4674 (2024)","journal-title":"J. Clin. Med."},{"key":"4686_CR198","doi-asserted-by":"publisher","first-page":"170174","DOI":"10.1016\/j.peptides.2019.170174","volume":"125","author":"SM Heimburger","year":"2020","unstructured":"S.M. Heimburger, N.C. Bergmann, R. Augustin, L.S. Gasbjerg, M.B. Christensen, F.K. Knop, Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease. Peptides. 125, 170174 (2020)","journal-title":"Peptides"},{"issue":"1","key":"4686_CR199","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12933-025-02806-5","volume":"24","author":"ZI Heged\u0171s","year":"2025","unstructured":"Z.I. Heged\u0171s, M.E. Jakab, T.G. Gergely, N.V. Sayour, A. Kov\u00e1cs, S. Antal et al., Tirzepatide, a dual GIP\/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide. Cardiovasc. Diabetol. 24(1), 253 (2025)","journal-title":"Cardiovasc. Diabetol."},{"issue":"10","key":"4686_CR200","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1161\/CIRCULATIONAHA.124.072679","volume":"151","author":"MR Zile","year":"2025","unstructured":"M.R. Zile, B.A. Borlaug, C.M. Kramer, S.J. Baum, S.E. Litwin, V. Menon et al., Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity. Circulation. 151(10), 656\u2013668 (2025)","journal-title":"Circulation"},{"issue":"4","key":"4686_CR201","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10741-024-10395-w","volume":"29","author":"YB Liu","year":"2024","unstructured":"Y.B. Liu, Q. Wang, Y.L. Song, X.M. Song, Y.C. Fan, L. Kong et al., Abnormal phosphorylation \/ dephosphorylation and Ca(2+) dysfunction in heart failure. Heart Fail. Rev. 29(4), 751\u2013768 (2024)","journal-title":"Heart Fail. Rev."},{"key":"4686_CR202","doi-asserted-by":"publisher","first-page":"1463547","DOI":"10.3389\/fendo.2024.1463547","volume":"15","author":"X Wang","year":"2024","unstructured":"X. Wang, X. Yang, X. Qi, G. Fan, L. Zhou, Z. Peng et al., Anti-atherosclerotic effect of incretin receptor agonists. Front. Endocrinol. 15, 1463547 (2024)","journal-title":"Front. Endocrinol."},{"key":"4686_CR203","doi-asserted-by":"publisher","first-page":"16718","DOI":"10.1038\/s41598-026-42437-8","volume":"16","author":"K Dan","year":"2026","unstructured":"K. Dan, J. Sanada, T. Kimura, Y. Iwamoto, T. Sugisaki, H. Iwamoto et al., Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mice. Sci. Rep. 16, 16718 (2026)","journal-title":"Sci. Rep."},{"issue":"24","key":"4686_CR204","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"S.J. Nicholls, I. Pavo, D.L. Bhatt, J.B. Buse, Del S. Prato, S.E. Kahn et al., Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl. J. Med. 393(24), 2409\u20132420 (2025)","journal-title":"N Engl. J. Med."},{"key":"4686_CR205","doi-asserted-by":"publisher","first-page":"113072","DOI":"10.1016\/j.diabres.2025.113072","volume":"231","author":"Y Iwasaki","year":"2026","unstructured":"Y. Iwasaki, T. Shimada, T. Kishimori, T. Kato, J. Koike, T. Matsumoto et al., Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin. Diabetes Res. Clin. Pract. 231, 113072 (2026)","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"Suppl 3","key":"4686_CR206","doi-asserted-by":"publisher","first-page":"iii137","DOI":"10.1093\/eurheartjsupp\/suaf032","volume":"27","author":"LAF Di Odoardo","year":"2025","unstructured":"Di L.A.F. Odoardo, O. Zucchetti, E. Sciatti, S. D\u2019Isa, E. D\u2019Elia, M. Senni, Obesity update: cardiovascular risk and therapeutic innovations (focus on semaglutide and tirzepatide). Eur. heart J. supplements: J. Eur. Soc. Cardiol. 27(Suppl 3), iii137\u2013iii42 (2025)","journal-title":"Eur. heart J. supplements: J. Eur. Soc. Cardiol."},{"key":"4686_CR207","doi-asserted-by":"publisher","first-page":"113877","DOI":"10.1016\/j.intimp.2024.113877","volume":"146","author":"Y Tian","year":"2025","unstructured":"Y. Tian, R. Tian, H. Juan, Y. Guo, P. Yan, Y. Cheng et al., GLP-1\/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K\/AKT mediated suppression of oxidative stress. Int. Immunopharmacol. 146, 113877 (2025)","journal-title":"Int. Immunopharmacol."},{"issue":"21","key":"4686_CR208","doi-asserted-by":"publisher","first-page":"e194749","DOI":"10.1172\/JCI194749","volume":"135","author":"ME van Cooper","year":"2025","unstructured":"M.E. Cooper, van D.H. Raalte, GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. J. Clin. Investig. 135(21), e194749 (2025)","journal-title":"J. Clin. Investig"},{"issue":"3","key":"4686_CR209","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s12020-024-03757-9","volume":"84","author":"I Caruso","year":"2024","unstructured":"I. Caruso, F. Giorgino, Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future. Endocrine. 84(3), 822\u2013835 (2024)","journal-title":"Endocrine"},{"issue":"2","key":"4686_CR210","doi-asserted-by":"publisher","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","volume":"301","author":"RO Crajoinas","year":"2011","unstructured":"R.O. Crajoinas, F.T. Oricchio, T.D. Pessoa, B.P. Pacheco, L.M. Lessa, G. Malnic et al., Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am. J. Physiol. Ren. Physiol. 301(2), F355\u2013F363 (2011)","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"2","key":"4686_CR211","doi-asserted-by":"publisher","first-page":"F231","DOI":"10.1152\/ajprenal.00432.2018","volume":"316","author":"L Tonneijck","year":"2019","unstructured":"L. Tonneijck, M.H.A. Muskiet, C.J. Blijdorp, M.M. Smits, J.W. Twisk, M.H.H. Kramer et al., Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus. Am. J. Physiol. Ren. Physiol. 316(2), F231\u2013F40 (2019)","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"6","key":"4686_CR212","doi-asserted-by":"publisher","first-page":"E747","DOI":"10.1152\/ajpendo.00374.2023","volume":"326","author":"BE McFarlin","year":"2024","unstructured":"B.E. McFarlin, K.L. Duffin, A. Konkar, Incretin and glucagon receptor polypharmacology in chronic kidney disease. Am. J. Physiol. Endocrinol. Metab. 326(6), E747\u2013E66 (2024)","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"3","key":"4686_CR213","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3390\/biomedicines12030657","volume":"12","author":"M Rroji","year":"2024","unstructured":"M. Rroji, G. Spasovski, Transforming Diabetes Care: The Molecular Pathways through Which GLP1-RAs Impact the Kidneys in Diabetic Kidney Disease. Biomedicines. 12(3), 657 (2024)","journal-title":"Biomedicines"},{"issue":"7","key":"4686_CR214","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.3390\/ijms26073050","volume":"26","author":"P Karakasis","year":"2025","unstructured":"P. Karakasis, D. Patoulias, P. Theofilis, K. Pamporis, M. Sagris, P.K. Vlachakis et al., GLP-1 Receptor Agonists and Myocardial Perfusion: Bridging Mechanisms to Clinical Outcomes. Int. J. Mol. Sci. 26(7), 3050 (2025)","journal-title":"Int. J. Mol. Sci."},{"key":"4686_CR215","doi-asserted-by":"publisher","first-page":"204201881986539","DOI":"10.1177\/2042018819865398","volume":"10","author":"MJB van Baar","year":"2019","unstructured":"van M.J.B. Baar, van der A.B. Aart, K. Hoogenberg, J.A. Joles, H.J.L. Heerspink, van D.H. Raalte, The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists. Ther. Adv. Endocrinol. Metab. 10, 2042018819865398 (2019)","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"2","key":"4686_CR216","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s11010-024-05066-1","volume":"480","author":"Y Yang","year":"2025","unstructured":"Y. Yang, Y. Wang, Y. Zhou, J. Deng, L. Wu, Tirzepatide alleviates oxidative stress and inflammation in diabetic nephropathy via IL-17 signaling pathway. Mol. Cell. Biochem. 480(2), 1241\u20131254 (2025)","journal-title":"Mol. Cell. Biochem."},{"key":"4686_CR217","doi-asserted-by":"publisher","first-page":"102355","DOI":"10.1016\/j.coph.2023.102355","volume":"69","author":"JC Ribeiro-Silva","year":"2023","unstructured":"J.C. Ribeiro-Silva, C.A.M. Tavares, A.C.C. Girardi, The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanisms. Curr. Opin. Pharmacol. 69, 102355 (2023)","journal-title":"Curr. Opin. Pharmacol."},{"issue":"2","key":"4686_CR218","doi-asserted-by":"publisher","first-page":"165","DOI":"10.22159\/ijap.2025v17i2.53156","volume":"17","author":"GA Alkhafaji","year":"2025","unstructured":"G.A. Alkhafaji, A.M. Janabi, Gip\/Glp-1 Dual Agonist Tirzepatide Ameliorates Renal Ischemia\/Reperfusion Damage in Rats. Int. J. Appl. Pharm. 17(2), 165\u2013173 (2025)","journal-title":"Int. J. Appl. Pharm."},{"key":"4686_CR219","doi-asserted-by":"publisher","first-page":"101895","DOI":"10.1016\/j.toxrep.2025.101895","volume":"14","author":"TM Al-Noshokaty","year":"2025","unstructured":"T.M. Al-Noshokaty, R. Abdelhamid, N.M. Abdelmaksoud, A. Khaled, M. Hossam, R. Ahmed et al., Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential. Toxicol. Rep. 14, 101895 (2025)","journal-title":"Toxicol. Rep."},{"issue":"14","key":"4686_CR220","doi-asserted-by":"publisher","first-page":"6962","DOI":"10.3390\/ijms26146962","volume":"26","author":"X Cao","year":"2025","unstructured":"X. Cao, N. Wang, M. Yang, C. Zhang, Lipid Accumulation and Insulin Resistance: Bridging Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease. Int. J. Mol. Sci. 26(14), 6962 (2025)","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"4686_CR221","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.3390\/ijms24043385","volume":"24","author":"AI Inceu","year":"2023","unstructured":"A.I. Inceu, M.A. Neag, A.E. Craciun, A.D. Buzoianu, Gut Molecules in Cardiometabolic Diseases: The Mechanisms behind the Story. Int. J. Mol. Sci. 24(4), 3385 (2023)","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"4686_CR222","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/dom.15410","volume":"26","author":"P Karakasis","year":"2024","unstructured":"P. Karakasis, D. Patoulias, N. Fragakis, A. Klisic, M. Rizzo, Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis. Diabetes Obes. Metab. 26(3), 1090\u20131104 (2024)","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"4686_CR223","doi-asserted-by":"publisher","first-page":"101282","DOI":"10.4239\/wjd.v16.i2.101282","volume":"16","author":"A Kamrul-Hasan","year":"2025","unstructured":"A. Kamrul-Hasan, S. Patra, D. Dutta, L. Nagendra, A. Muntahi-Reza, S. Borozan et al., Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis. World J. Diabetes. 16(2), 101282 (2025)","journal-title":"World J. Diabetes"},{"issue":"6","key":"4686_CR224","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2174\/1570180820666230130153219","volume":"21","author":"S Jaswal","year":"2024","unstructured":"S. Jaswal, P. Bisht, R. Patel, D. Parveen, G.D. Gupta, S.K. Verma, Tirzepatide: A First-in-class Twincretin for the Management of Type 2 Diabetes. Lett. Drug Des. Discovery. 21(6), 991\u2013997 (2024)","journal-title":"Lett. Drug Des. Discovery"},{"key":"4686_CR225","doi-asserted-by":"publisher","first-page":"1402583","DOI":"10.3389\/fendo.2024.1402583","volume":"15","author":"S Corrao","year":"2024","unstructured":"S. Corrao, C. Pollicino, D. Maggio, A. Torres, C. Argano, Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence. Front. Endocrinol. 15, 1402583 (2024)","journal-title":"Front. Endocrinol."},{"issue":"3","key":"4686_CR226","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"A.M. Jastreboff, L.J. Aronne, N.N. Ahmad, S. Wharton, L. Connery, B. Alves et al., Tirzepatide Once Weekly for the Treatment of Obesity. N Engl. J. Med. 387(3), 205\u2013216 (2022)","journal-title":"N Engl. J. Med."},{"issue":"1","key":"4686_CR227","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7570\/jomes22067","volume":"32","author":"R Sinha","year":"2023","unstructured":"R. Sinha, D. Papamargaritis, J.A. Sargeant, M.J. Davies, Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. J. Obes. Metab. Syndr. 32(1), 25\u201345 (2023)","journal-title":"J. Obes. Metab. Syndr."},{"issue":"10","key":"4686_CR228","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"A.M. Jastreboff, le C.W. Roux, A. Stefanski, L.J. Aronne, B. Halpern, S. Wharton et al., Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl. J. Med. 392(10), 958\u2013971 (2025)","journal-title":"N Engl. J. Med."},{"issue":"7","key":"4686_CR229","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1001\/jama.2024.9217","volume":"332","author":"L Zhao","year":"2024","unstructured":"L. Zhao, Z. Cheng, Y. Lu, M. Liu, H. Chen, M. Zhang et al., Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. Jama. 332(7), 551\u2013560 (2024)","journal-title":"Jama"},{"issue":"1","key":"4686_CR230","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"L.J. Aronne, D.B. Horn, le C.W. Roux, W. Ho, B.L. Falcon, E. Gomez Valderas et al., Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl. J. Med. 393(1), 26\u201336 (2025)","journal-title":"N Engl. J. Med."},{"issue":"2","key":"4686_CR231","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/obesities5020026","volume":"5","author":"M Sallam","year":"2025","unstructured":"M. Sallam, J. Snygg, S.E. Ghandour, M. Sallam, Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review. Obesities. 5(2), 26 (2025)","journal-title":"Obesities"},{"issue":"1","key":"4686_CR232","doi-asserted-by":"publisher","first-page":"e13841","DOI":"10.1111\/obr.13841","volume":"26","author":"JI Mechanick","year":"2025","unstructured":"J.I. Mechanick, W.S. Butsch, S.M. Christensen, O. Hamdy, Z. Li, C.M. Prado et al., Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obes. reviews: official J. Int. Association Study Obes. 26(1), e13841 (2025)","journal-title":"Obes. reviews: official J. Int. Association Study Obes."},{"issue":"5","key":"4686_CR233","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1111\/dom.16275","volume":"27","author":"M Look","year":"2025","unstructured":"M. Look, J.P. Dunn, R.F. Kushner, D. Cao, C. Harris, T.H. Gibble et al., Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes. Metab. 27(5), 2720\u20132729 (2025)","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"4686_CR234","first-page":"98","volume":"11","author":"J Zinn","year":"2025","unstructured":"J. Zinn, L. Poretsky, Skeletal Muscle Mass and Body Weight Fall Proportionally With Use of Dual Glucagon-Like Peptide 1\/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Tirzepatide: Case Report and Review of Literature. AACE Clin. case Rep. 11(2), 98\u2013101 (2025)","journal-title":"AACE Clin. case Rep."},{"issue":"6","key":"4686_CR235","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1002\/jcsm.13346","volume":"14","author":"Y Takahashi","year":"2023","unstructured":"Y. Takahashi, H. Fujita, Y. Seino, S. Hattori, S. Hidaka, T. Miyakawa et al., Gastric inhibitory polypeptide receptor antagonism suppresses intramuscular adipose tissue accumulation and ameliorates sarcopenia. J. cachexia sarcopenia muscle. 14(6), 2703\u20132718 (2023)","journal-title":"J. cachexia sarcopenia muscle"},{"key":"4686_CR236","doi-asserted-by":"publisher","first-page":"107927","DOI":"10.1016\/j.phrs.2025.107927","volume":"220","author":"A Ceasovschih","year":"2025","unstructured":"A. Ceasovschih, A. Asaftei, M.G. Lupo, S. Kotlyarov, H. Bartu\u0161kov\u00e1, A. Balta et al., Glucagon-like peptide-1 receptor agonists and muscle mass effects. Pharmacol. Res. 220, 107927 (2025)","journal-title":"Pharmacol. Res."},{"issue":"1","key":"4686_CR237","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/med.22070","volume":"45","author":"JP Psaltis","year":"2025","unstructured":"J.P. Psaltis, J.A. Marathe, M.T. Nguyen, R. Le, C.A. Bursill, C.S. Marathe et al., Incretin-based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future. Med. Res. Rev. 45(1), 29\u201365 (2025)","journal-title":"Med. Res. Rev."},{"issue":"1","key":"4686_CR238","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.14831","volume":"25","author":"C De Block","year":"2023","unstructured":"De C. Block, C. Bailey, C. Wysham, A. Hemmingway, S.E. Allen, J. Peleshok, Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. Diabetes Obes. Metab. 25(1), 3\u201317 (2023)","journal-title":"Diabetes Obes. Metab."},{"issue":"10295","key":"4686_CR239","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"J. Rosenstock, C. Wysham, J.P. Fr\u00edas, S. Kaneko, C.J. Lee, L. Fern\u00e1ndez Land\u00f3 et al., Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (London England). 398(10295), 143\u2013155 (2021)","journal-title":"Lancet (London England)"},{"issue":"6","key":"4686_CR240","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Frias","year":"2021","unstructured":"J.P. Frias, M.J. Davies, J. Rosenstock, F.C. Perez Manghi, L. Fernandez Lando, B.K. Bergman et al., Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl. J. Med. 385(6), 503\u2013515 (2021)","journal-title":"N Engl. J. Med."},{"issue":"10313","key":"4686_CR241","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del S. Prato, S.E. Kahn, I. Pavo, G.J. Weerakkody, Z. Yang, J. Doupis et al., Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 398(10313), 1811\u20131824 (2021)","journal-title":"Lancet"},{"issue":"Supplement1","key":"4686_CR242","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2337\/db21-80-LB","volume":"70","author":"D Dahl","year":"2021","unstructured":"D. Dahl, Y. Onishi, P. Norwood, R. Huh, H. Patel, \u00c1. Rodr\u00cdGuez, 80-LB: Tirzepatide, a Dual GIP\/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5). Diabetes. 70(Supplement1), 80\u2013LB (2021)","journal-title":"Diabetes"},{"issue":"6","key":"4686_CR243","first-page":"503","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"J.P. Fr\u00edas, M.J. Davies, J. Rosenstock, F.C.P. Manghi, L.F. Land\u00f3, B.K. Bergman et al., Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.New England. J. Med. 385(6), 503\u2013515 (2021)","journal-title":"J. Med."},{"issue":"17","key":"4686_CR244","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1001\/jama.2023.20294","volume":"330","author":"J Rosenstock","year":"2023","unstructured":"J. Rosenstock, J.P. Frias, H.W. Rodbard, S. Tofe, E. Sears, R. Huh et al., Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. JAMA 330(17), 1631\u20131640 (2023)","journal-title":"JAMA"},{"issue":"9","key":"4686_CR245","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S2213-8587(22)00187-5","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"T. Kadowaki, R. Chin, A. Ozeki, T. Imaoka, Y. Ogawa, Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 10(9), 634\u2013644 (2022)","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4686_CR246","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","volume":"267","author":"SJ Nicholls","year":"2024","unstructured":"S.J. Nicholls, D.L. Bhatt, J.B. Buse, S.D. Prato, S.E. Kahn, A.M. Lincoff et al., Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am. Heart J. 267, 1\u201311 (2024)","journal-title":"Am. Heart J."},{"issue":"9","key":"4686_CR247","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","volume":"10","author":"N Inagaki","year":"2022","unstructured":"N. Inagaki, M. Takeuchi, T. Oura, T. Imaoka, Y. Seino, Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 10(9), 623\u2013633 (2022)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"4686_CR248","doi-asserted-by":"publisher","first-page":"348","DOI":"10.7570\/jomes24008","volume":"33","author":"MU Mahar","year":"2024","unstructured":"M.U. Mahar, O. Mahmud, S. Ahmed, S.A. Qureshi, W.G. Kakar, S.S. Fatima, The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Obes. Metab. Syndr. 33(4), 348\u2013359 (2024)","journal-title":"J. Obes. Metab. Syndr."},{"issue":"2","key":"4686_CR249","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1210\/clinem\/dgab722","volume":"107","author":"V Pirro","year":"2022","unstructured":"V. Pirro, K.D. Roth, Y. Lin, J.A. Willency, P.L. Milligan, J.M. Wilson et al., Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes. J. Clin. Endocrinol. Metab. 107(2), 363\u2013378 (2022)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Supplement2","key":"4686_CR250","first-page":"ehaa946","volume":"41","author":"G Ruotolo","year":"2020","unstructured":"G. Ruotolo, K.D. Roth, P.L. Milligan, Y. Lin, J.M. Wilson, V. Pirro et al., Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on lipid profiling in patients with type 2 diabetes. Eur. Heart J. 41(Supplement2), ehaa946 (2020)","journal-title":"Eur. Heart J."},{"issue":"11","key":"4686_CR251","doi-asserted-by":"publisher","first-page":"100445","DOI":"10.1016\/j.jlr.2023.100445","volume":"64","author":"R Ly","year":"2023","unstructured":"R. Ly, B.C. MacIntyre, S.M. Philips, C. McGlory, D.M. Mutch, P. Britz-McKibbin, Lipidomic studies reveal two specific circulating phosphatidylcholines as surrogate biomarkers of the omega-3 index. J. Lipid Res. 64(11), 100445 (2023)","journal-title":"J. Lipid Res."},{"key":"4686_CR252","doi-asserted-by":"crossref","unstructured":"G. Ruotolo, K.D. Roth, P.L. Milligan, Y. Lin, J.M. Wilson, V. Pirro et al., Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on lipid profiling in patients with type 2 diabetes. Eur. Heart J. 41(Supplement_2).:ehaa946-3056 (2020)","DOI":"10.1093\/ehjci\/ehaa946.3056"},{"key":"4686_CR253","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.mito.2014.05.007","volume":"17","author":"M Adeva-Andany","year":"2014","unstructured":"M. Adeva-Andany, M. Lopez-Ojen, R. Funcasta-Calderon, E. Ameneiros-Rodriguez, C. Donapetry-Garcia, M. Vila-Altesor et al., Comprehensive review on lactate metabolism in human health. Mitochondrion. 17, 76\u2013100 (2014)","journal-title":"Mitochondrion"},{"issue":"10160","key":"4686_CR254","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","volume":"392","author":"JP Frias","year":"2018","unstructured":"J.P. Frias, M.A. Nauck, J. Van, M.E. Kutner, X. Cui, C. Benson et al., Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 392(10160), 2180\u20132193 (2018)","journal-title":"Lancet"},{"key":"4686_CR255","unstructured":"A Study of Tirzepatide (LY3298176), in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5) [Internet]. 2024 [cited 2025-02-22]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05822830"},{"issue":"7","key":"4686_CR256","first-page":"e88390","volume":"17","author":"I Hong","year":"2025","unstructured":"I. Hong, R.A. Hidalgo Ramos, S. Dufner Krieger, D. Secades, M. Ortiz, L.F. Moya Porras et al., Effects of Tirzepatide on Low-Density Lipoprotein Cholesterol Levels in Adults: A Systematic Review. Cureus. 17(7), e88390 (2025)","journal-title":"Cureus"},{"issue":"19","key":"4686_CR257","first-page":"1165","volume":"110","author":"HM Krumholz","year":"2024","unstructured":"H.M. Krumholz, de J.A. Lemos, N. Sattar, B. Linetzky, P. Sharma, C.J. Mast et al., Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial. Heart (British Cardiac Society). 110(19), 1165\u20131171 (2024)","journal-title":"Heart (British Cardiac Society)"},{"issue":"19","key":"4686_CR258","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/heartjnl-2024-324170","volume":"110","author":"HM de Krumholz","year":"2024","unstructured":"H.M. Krumholz, de J.A. Lemos, N. Sattar, B. Linetzky, P. Sharma, C.J. Mast et al., Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial. Heart. 110(19), 1165\u20131171 (2024)","journal-title":"Heart"},{"issue":"12","key":"4686_CR259","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1111\/dom.15272","volume":"25","author":"M Kanbay","year":"2023","unstructured":"M. Kanbay, S. Copur, D. Siriopol, A.B. Yildiz, A. Gaipov, van D.H. Raalte et al., Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials. Diabetes Obes. Metab. 25(12), 3766\u20133778 (2023)","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"4686_CR260","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12933-023-01797-5","volume":"22","author":"I Lingvay","year":"2023","unstructured":"I. Lingvay, O. Mosenzon, K. Brown, X. Cui, C. O\u2019Neill, L. Fern\u00e1ndez Land\u00f3 et al., Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovasc. Diabetol. 22(1), 66 (2023)","journal-title":"Cardiovasc. Diabetol."},{"key":"4686_CR261","doi-asserted-by":"crossref","unstructured":"I. Lingvay, O. Mosenzon, K. Brown, X. Cui, L.F. Lando, H. Patel, 716-P: Systolic Blood Pressure Reduction with Tirzepatide across SURPASS Program: A Mediation Analysis Using Weight Loss as a Factor. Diabetes. 71(Supplement_1).:716-P (2022)","DOI":"10.2337\/db22-716-P"},{"issue":"4","key":"4686_CR262","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/HYPERTENSIONAHA.123.22022","volume":"81","author":"JA de Lemos","year":"2024","unstructured":"de J.A. Lemos, B. Linetzky, le C.W. Roux, L.J. Laffin, W. Vongpatanasin, L. Fan et al., Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index >\/=27 kg\/m(2): SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy. Hypertension. 81(4), e41\u2013e3 (2024)","journal-title":"Hypertension"},{"issue":"Suppl1","key":"4686_CR263","first-page":"A10370","volume":"146","author":"JA De Lemos","year":"2022","unstructured":"De J.A. Lemos, le C.W. Roux, H. Mao, N.N. Ahmad, zhang, M. Bunck et al., Abstract 10370: Effects of Tirzepatide on 24-Hour Ambulatory Blood Pressure and Heart Rate in Adults With Obesity - Results From the SURMOUNT-1 Ambulatory Blood Pressure Monitoring Sub-Study. Circulation. 146(Suppl1), A10370\u2013A (2022)","journal-title":"Circulation"},{"issue":"5","key":"4686_CR264","first-page":"427","volume":"392","author":"M Packer","year":"2025","unstructured":"M. Packer, M.R. Zile, C.M. Kramer, S.J. Baum, S.E. Litwin, V. Menon et al., Tirzepatide Heart Fail. Preserved Ejection Fraction Obes. 392(5), 427\u2013437 (2025)","journal-title":"Tirzepatide Heart Fail. Preserved Ejection Fraction Obes."},{"issue":"6","key":"4686_CR265","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.2337\/dc19-1892","volume":"43","author":"ML Hartman","year":"2020","unstructured":"M.L. Hartman, A.J. Sanyal, R. Loomba, J.M. Wilson, A. Nikooienejad, R. Bray et al., Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. Diabetes Care. 43(6), 1352\u20131355 (2020)","journal-title":"Diabetes Care"},{"key":"4686_CR266","doi-asserted-by":"crossref","unstructured":"M.L. Hartman, A. Sanyal, R. Loomba, J.M. Wilson, R. Bray, A. Nikooienejad et al., 134-OR: Effects of Tirzepatide (TZP), a Novel Dual GIP and GLP-1 Receptor Agonist, on Biomarkers of Nonalcoholic Steatohepatitis (NASH) in Patients with T2D. Diabetes. 68(Supplement_1):134-OR (2019)","DOI":"10.2337\/db19-134-OR"},{"issue":"4","key":"4686_CR267","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/jcm14041303","volume":"14","author":"M Infante","year":"2025","unstructured":"M. Infante, F. Silvestri, N. Padilla, F. Pacifici, D. Pastore, M.M. Pinheiro et al., Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults. J. Clin. Med. 14(4), 1303 (2025)","journal-title":"J. Clin. Med."},{"issue":"1","key":"4686_CR268","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/apt.18042","volume":"60","author":"R Vuppalanchi","year":"2024","unstructured":"R. Vuppalanchi, R. Loomba, A.J. Sanyal, A. Nikooie, Y. Tang, D.A. Robins et al., Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures. Aliment. Pharmacol. Ther. 60(1), 17\u201332 (2024)","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"4686_CR269","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","volume":"10","author":"A Gastaldelli","year":"2022","unstructured":"A. Gastaldelli, K. Cusi, L. Fernandez Lando, R. Bray, B. Brouwers, A. Rodriguez, Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 10(6), 393\u2013406 (2022)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"4686_CR270","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/S2213-8587(25)00027-0","volume":"13","author":"N Sattar","year":"2025","unstructured":"N. Sattar, I.J. Neeland, O. Dahlqvist Leinhard, L. Fernandez Lando, R. Bray, J. Linge et al., Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 13(6), 482\u2013493 (2025)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"13","key":"4686_CR271","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"A. Malhotra, R.R. Grunstein, I. Fietze, T.E. Weaver, S. Redline, A. Azarbarzin et al., Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl. J. Med. 391(13), 1193\u20131205 (2024)","journal-title":"N Engl. J. Med."},{"issue":"Supplement1","key":"4686_CR272","doi-asserted-by":"publisher","first-page":"A23","DOI":"10.1093\/sleepadvances\/zpae070.064","volume":"5","author":"R Grunstein","year":"2024","unstructured":"R. Grunstein, A. Malhotra, I. Fietze, T. Wever, J. Dunn, S. Chakladar et al., O064 Tirzepatide reduced sleep apnea severity in adults with obstructive sleep apnea and obesity: results from the SURMOUNT-OSA trial. Sleep. Adv. 5(Supplement1), A23\u2013A (2024)","journal-title":"Sleep. Adv."},{"issue":"13","key":"4686_CR273","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"A. Malhotra, R.R. Grunstein, I. Fietze, T.E. Weaver, S. Redline, A. Azarbarzin et al., Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N. Engl. J. Med. 391(13), 1193\u20131205 (2024)","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"4686_CR274","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s13679-024-00592-x","volume":"13","author":"G Beccuti","year":"2024","unstructured":"G. Beccuti, F. Bioletto, M. Parasiliti-Caprino, A. Benso, E. Ghigo, A. Cicolin et al., Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials. Curr. Obes. Rep. 13(4), 739\u2013742 (2024)","journal-title":"Curr. Obes. Rep."},{"issue":"7","key":"4686_CR275","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1513\/AnnalsATS.202409-923OC","volume":"22","author":"AE Henney","year":"2025","unstructured":"A.E. Henney, D.R. Riley, M. Anson, M. Heague, G. Hernadez, U. Alam et al., Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence. Ann. Am. Thorac. Soc. 22(7), 1042\u20131052 (2025)","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"11","key":"4686_CR276","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","volume":"10","author":"HJL Heerspink","year":"2022","unstructured":"H.J.L. Heerspink, N. Sattar, I. Pavo, A. Haupt, K.L. Duffin, Z. Yang et al., Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 10(11), 774\u2013785 (2022)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10402","key":"4686_CR277","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"W.T. Garvey, J.P. Frias, A.M. Jastreboff, le C.W. Roux, N. Sattar, D. Aizenberg et al., Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 402(10402), 613\u2013626 (2023)","journal-title":"Lancet"},{"issue":"9","key":"4686_CR278","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/ph18091261","volume":"18","author":"Z Song","year":"2025","unstructured":"Z. Song, Y. Tang, M. Peng, R. Han, P. He, Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP\/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis. Pharmaceuticals (Basel Switzerland). 18(9), 1261 (2025)","journal-title":"Pharmaceuticals (Basel Switzerland)"},{"issue":"6","key":"4686_CR279","doi-asserted-by":"publisher","first-page":"e70032","DOI":"10.1002\/osp4.70032","volume":"10","author":"ABM Kamrul-Hasan","year":"2024","unstructured":"A.B.M. Kamrul-Hasan, S. Mondal, D. Dutta, L. Nagendra, M.R. Kabir, J.M. Pappachan, Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta-Analysis. Obes. Sci. Pract. 10(6), e70032 (2024)","journal-title":"Obes. Sci. Pract."},{"issue":"1","key":"4686_CR280","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s13300-025-01804-w","volume":"17","author":"RJ Galindo","year":"2026","unstructured":"R.J. Galindo, A.Y.Y. Cheng, C. Longuet, M. Ai, T. Coskun, R. Malik et al., Insights into the Mechanism of Action of Tirzepatide: A Narrative Review. Diabetes Ther. 17(1), 19\u201340 (2026)","journal-title":"Diabetes Ther."},{"key":"4686_CR281","doi-asserted-by":"publisher","first-page":"1008128","DOI":"10.37349\/eds.2025.1008128","volume":"3","author":"A Lonardo","year":"2025","unstructured":"A. Lonardo, R. Weiskirchen, Tirzepatide in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a novel star on the horizon? Explor. Drug Sci. 3, 1008128 (2025)","journal-title":"Explor. Drug Sci."},{"key":"4686_CR282","doi-asserted-by":"publisher","first-page":"100220","DOI":"10.1016\/j.metop.2022.100220","volume":"16","author":"IG Lempesis","year":"2022","unstructured":"I.G. Lempesis, J. Liu, M. Dalamaga, The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity. Metabol Open. 16, 100220 (2022)","journal-title":"Metabol Open."},{"issue":"21","key":"4686_CR283","doi-asserted-by":"publisher","first-page":"10741","DOI":"10.3390\/ijms262110741","volume":"26","author":"D Viana","year":"2025","unstructured":"D. Viana, A.L. Invitti, E. Schor, Tirzepatide as a Potential Disease-Modifying Therapy in Lipedema: A Narrative Review on Bridging Metabolism, Inflammation, and Fibrosis. Int. J. Mol. Sci. 26(21), 10741 (2025)","journal-title":"Int. J. Mol. Sci."},{"key":"4686_CR284","doi-asserted-by":"publisher","first-page":"2876156","DOI":"10.1155\/ije\/2876156","volume":"2025","author":"J Ghaleb","year":"2025","unstructured":"J. Ghaleb, K.K. Khouzami, N. Nassif, P. Attieh, M.F.A. Ajlani, J.B. Sleiman et al., Unveiling Tirzepatide\u2019s Therapeutic Spectrum: A Dual GIP\/GLP-1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health. Int. J. Endocrinol. 2025, 2876156 (2025)","journal-title":"Int. J. Endocrinol."},{"issue":"11","key":"4686_CR285","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"T.A. Wadden, A.M. Chao, S. Machineni, R. Kushner, J. Ard, G. Srivastava et al., Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat. Med. 29(11), 2909\u20132918 (2023)","journal-title":"Nat. Med."},{"issue":"9","key":"4686_CR286","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/oby.24332","volume":"33","author":"CSP Lam","year":"2025","unstructured":"C.S.P. Lam, A. Rodriguez, A. Aminian, E. Ferrannini, H.J.L. Heerspink, A.M. Jastreboff et al., Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial. Obes. (Silver Spring Md). 33(9), 1645\u20131656 (2025)","journal-title":"Obes. (Silver Spring Md)"},{"issue":"5","key":"4686_CR287","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s13300-024-01561-2","volume":"15","author":"Y Bi","year":"2024","unstructured":"Y. Bi, S. Lu, J. Tang, L. Du, L. Ji, Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups. Diabetes Ther. 15(5), 1125\u20131137 (2024)","journal-title":"Diabetes Ther."},{"issue":"10","key":"4686_CR288","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s13300-025-01784-x","volume":"16","author":"GP Fadini","year":"2025","unstructured":"G.P. Fadini, Can Dual Incretin Receptor Agonists Exert Better Cardiovascular Protection than Selective GLP-1 Receptor Agonists? Highlights from SURPASS-CVOT. Diabetes Ther. 16(10), 1893\u20131898 (2025)","journal-title":"Diabetes Ther."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04686-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04686-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04686-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:03:51Z","timestamp":1782929031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04686-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":288,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4686"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04686-5","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"216"}}